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Conventional platinum(II)-based anticancer drugs present a variety of clinical issues, including 
numerous severe side-effects due to their non-selective mechanism of action. The discovery of G-
Quadruplex DNA (G4-DNA) has opened a new area of research for the design of selective 
anticancer agents with reduced side-effects. Various molecules, both organic and inorganic have 
been shown to selectively stabilise G4-DNA. In particular, platinum(II) complexes have shown to 
exhibit strong G4-DNA binding affinity, such as those consisting of 1,10-phenantrholine (Phen)-
based ligands. Previous studies have shown [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)2]
2+ to be 
a strong G4-DNA binder. Building upon this background, the aim of this project is to design 
platinum(II)-based G4-DNA stabilisers consisting of Phen and 2,2′-bipyridine (Bpy)-based ligands 
and with particular focus on the 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4phen) ligand.  
Seven novel asymmetric platinum(II) complexes were synthesised using improved synthetic 
methods and complexes were subsequently purified using flash chromatography. These complexes 
were characterised using high pressure liquid chromatography (HPLC), nuclear magnetic 
resonance (NMR) spectroscopy, high resolution mass spectroscopy (HR-MS) and ultraviolet-
visible (UV-Vis) spectroscopy. Six of the resulting complexes consisted of the Me4phen ligand. 
Five complexes consisted of two Phen-based ligands, while two consisted of one coordinated 
Phen-based ligand and one coordinated Bpy-based ligand.  
The binding interactions of the synthesised complexes were determined using docking simulations, 
circular dichroism (CD) and electron spray ionisation mass spectroscopy (ESI-MS) and their 
efficacy was determined using cytotoxicity assays. Docking simulations indicated that the 
complexes with larger aromatic surface areas exhibit the best binding affinity (i.e. [Pt(3,4,7,8-
tetramethyl-1,10-phenanthroline)(pyrazino[2,3-f]1,10-phenanthroline)]Cl2, P4P6). However, 
docking simulations did not correlate with CD and ESI-MS binding experiments, with [Pt(3,4,7,8-
tetramethyl-1,10-phenanthroline)(4,7-dimethyl-1,10-phenanthroline)]Cl2 (P4P2) being the most 
potent G4-DNA stabiliser in vitro. Cytotoxicity assays on a number of cancer cell lines were 
performed to identify any correlations that exist between G4-DNA binding affinity and 
cytotoxicity. No correlations were identified, suggesting that other mechanisms of actions may be 
contributing to cytotoxic effects. Complex [Pt(5,6-dimethyl-1,10-phenanthroline)(1,10-




in cytotoxicity assays, showing up to a 5-fold better activity than cisplatin in pancreatic (MIA) and 
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Cancer is a disease characterised by abnormal cellular growth which has the potential to spread to 
other tissues of the body and is one of the leading causes of death worldwide.1 Despite the gigantic 
effort in search for more effective anticancer drugs, the prognosis of cancer remains very 
unfavourable for the cancer patient.1 The incidence of cancer has increased in the majority of 
countries since 1990, where various factors can be attributed to this worrying trend.2 These factors 
include: obesity, smoking, a lack of physical activity, an increasing ageing population and a change 
in reproductive patterns.3 According to projections from the International Agency for Research on 
Cancer, there were a total of 17 million new cancer cases and 9.5 million cancer-related deaths 
globally in 2018.4 Alarmingly, this trajectory is expected in increase to 27.5 million new cancer 
cases and 16.3 million cancer-related deaths by 2040, making cancer a major threat to public health 
worldwide.4 In Australia alone, there were approximately 140,000 new cancer cases and 50,000 
cancer related deaths in 2018.5 Cancer has a profound economic impact in terms of health care 
costs and productivity.6 In Australia, cancer costs exceed $4.5 billion per year, accounting for 6.9% 
of total health system costs.7  
 
Figure 1-1. Number of new cases and the number of deaths for the five most commonly 


























1.2 Clinically used Platinum(II) Anticancer Drugs 
The discovery of conventional platinum(II) based anticancer drugs began in 1961, when Barnett 
Rosenberg observed that the bacterial cell proliferation of Escherichia coli was inhibited within 
an electric field.9 It was found that E. coli began to grow into long filamentous rods which were 
up to 400 times their usual length (Figure 1-2).9 After testing many experimental variables, 
Rosenberg hypothesised that the product of electrolysis, [(NH4)2PtCl6], produced by platinum 
electrodes was the causative agent.10 However, it was later confirmed by Loretta Van Camp that 
it was the photochemical by-products of [(NH4)2PtCl6], (cis-[Pt(NH3)2Cl4] and cis-[Pt(NH3)2Cl2]) 
that were actually the causative agents.10 The more potent of the two photochemical by-products 
was found to be cis-[Pt(NH3)2Cl2] (cisplatin, Figure 1-3). Consequently, cisplatin was later 
approved by the United States Food and Drug Administration for the treatment of testicular and 
ovarian cancers in 1978.10, 11 Since the approval of cisplatin, two analogues of this conventional 
drug, carboplatin and oxaliplatin (Figure 1-3) have been approved for worldwide use.12 
Carboplatin exhibits less side-effects than cisplatin,13 while oxaliplatin is effective against tumours 
which have developed an acquired resistance towards both cisplatin and carboplatin.14 
 
Figure 1-2. Normal (left) and oversized filamentous E. coli (right) which were under the 





Cisplatin and its analogues (Figure 1-3) are known to act by the same mechanism of action (Figure 
1-4).16 Cisplatin circulates the blood where it remains relatively stable, as the chloride 
concentration in the blood stream remains high (>100 mM).17, 18 Upon entering the cell via passive 
diffusion as well as carrier-mediated transport proteins (mainly organic cation transporters and the 
copper influx transporter, CTR1), the chloride ligands are displaced by water ligands as this is 
favoured by the low chloride concentration in the cytoplasm (4-20 mM).18 Once inside the cell, 
conventional platinum(II) based drugs covalently bind to various biomacromolecules such as 
proteins, but most notably they form both intra- and inter-strand adducts, preferentially binding to 
the N7 atom of guanine of DNA.12, 19 Consequently, the disruption of the DNA structure results in 
apoptosis through mechanisms such as mitochondrial pathways, calcium signalling and death 
receptors.20 Additionally, the formation of DNA adducts prevent DNA replication and 
transcription and therefore cancer cell division is prevented.20 
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Figure 1-3. Molecular structures of current platinum-based anticancer drugs which have received 
worldwide approval: cisplatin (1), oxaliplatin (2) and carboplatin (3.).  
 
Even though conventional platinum(II) based anticancer drugs are used in 50-70% of 
chemotherapy regimens, they are not without drawbacks.21 Despite the positive properties of 
conventional drugs, they are poisons, as their mechanism of action is not selective towards cancer 
cells.18 The dose at which these drugs can be safely administered is limited by the severe side-
effects experienced by cancer patients.22 Side-effects include: nausea, vomiting, 
myelosuppression, immunosuppression, neurotoxicity, nephrotoxicity, hearing loss and other cell 
damaging effects.20 The side-effects due to conventional drugs are commonly so severe that a 
recent retrospective Australian study found that 73% of cancer patients receiving platinum-based 





Figure 1-4. Mechanism of action of cisplatin. 
 
Furthermore, both acquired and intrinsic resistance is also an issue.24, 25 Acquired resistance occurs 
when a tumour is originally susceptible to the anticancer drug but later becomes resistant.20 On the 
other hand, if the tumour is resistant to a drug from the very beginning of treatment, the tumour is 
said to be intrinsically resistant.20 Mechanisms of acquired resistance to cisplatin include: drug 
inactivation by an increased production of thiols (e.g. gluthionine), decreased cellular drug 
accumulation, increased drug efflux, increased nucleotide excision-repair levels and decreased 
mismatch-repair activity.20 Cross resistance is also an issue with cisplatin and carboplatin and the 
main cause is the over-expression of a specific ATP-binding cassette (ABC) transporter known as 




known as the main contributor of efflux of platinum-based drugs from the cell.20 Oxaliplatin was 
shown to be more effective against tumours which have developed an acquired to both cisplatin 
and carboplatin and is most important for treating colorectal cancers.14, 26 Oxaliplatin is effective 
at avoiding mechanisms which contribute to acquired resistance. For example, certain damage-
recognition proteins and mismatch repair proteins are known to bind to oxaliplatin-GG adducts 
with a much lower affinity than cisplatin-GG adducts. Additionally oxaliplatin has no cross-
resistance with both cisplatin and carboplatin.20 To help overcome resistance to conventional 
platinum-based anticancer drugs, combinational therapy is used (i.e. the use of 2-3 drugs of 
different mechanisms of actions), since the likelihood that a tumour is resistant to multiple drugs 
is small.27 For example, oxaliplatin is likely to be used in combination with 5-fluorouracil and 
gemcitabine.28, 29 
In addition to the above issues, numerous other clinical challenges exist such as low 
bioavailability,30 low solubility31 and a narrow spectrum of activity.21 All of these underlying 
issues with these conventional platinum-based drugs have instigated the search for novel and 
improved platinum-based anticancer drugs which act by a different mechanism of action to 
conventional drugs. Multiple strategies have been employed in an attempt to solve these issues. 
These include: coordinating oestrogen-based ligands to a platinum centre to increase 
lipophilicity,32 the use of carbohydrate ligands to improve selectivity,32 the design of platinum(IV) 
prodrugs to improve selectivity and combat resistance33 and the use of nanoscale coordination 
polymers to improve drug delivery.34 
Other than the conventional drugs already mentioned, other platinum-based drugs are also used in 
the clinic, however they have received limited worldwide approval. These include nedaplatin, 
heptaplatin and lobaplatin (Figure 1-5). Nedaplatin has only gained regulatory approval in Japan 
and contains a novel structure consisting of a glycolate ligand in place of the two chloride ligands 
found in cisplatin, which allows for greater water solubility.12, 35 Nedaplatin is primarily used for 
treating cancers of the head and neck as well as lung cancers and has the same mechanism of action 
as cisplatin.12, 35 It has also been found that nedaplatin has less renal and gastrointestinal toxicity 
than cisplatin and is less neurotoxic and nephrotoxic when compared to both cisplatin and 
carboplatin.35 Heptaplatin is marketed in Korea for treating gastric cancer and contains a malonate 




ligand.12 The two chiral centres in the molecule both have R stereochemistry.12 Lobaplatin is a 
derivative of heptaplatin which contains a cyclobutane ring joined with the seven-membered 
chelate ring when compared to heptaplatin. Although developed in Germany and tested in a variety 
of countries worldwide, lobaplatin is only approved in China for the treatment of chronic 
myelogenous leukemia, small lung carcinoma and metastatic breast cancer.12 Lobaplatin has also 
shown promising activity towards ovarian cancer, oesophageal cancer, colorectal cancer and 
hepatocellular carcinoma.36 
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Figure 1-5. Molecular structures of clinically used platinum-based anticancer drugs which have 
not received worldwide approval: nedaplatin (4), lobaplatin (5) and heptaplatin (6).  
 
1.3 Alkylating agents 
Alkylating agents, when compared to cisplatin and its analogues (i.e. metalling agents), are highly 
electrophilic organic compounds which act by reacting with nucleophilic groups on DNA, 
resulting in the formation of covalent bonds.37 The formation of DNA adducts leads to the same 
end result as with conventional platinum(II) based drugs, the inhibition of DNA replication and 
transcription, resulting in cancer cell death.38 The most commonly used alkylating agents are by 
far the nitrogen mustards, while aziridines, epoxides, alkyl sulfonates and nitrosoureas are less 
commonly used. Out of all the nitrogen mustards tested, only five are commonly used in the clinic. 
These are mechlorethamine (the first nitrogen mustard to be approved), as well as ifosfamide, 
melphalan, chlorambucil and cyclophosphamide (Figure 1-6).37 Unfortunately, selectivity, dose 






Figure 1-6. Molecular structure of common clinically used alkylating agents. 
 
The cyclophosphamide prodrug (8) is one of the most frequently used antineoplastic agents in 
chemotherapy and the most commonly used alkylating agent.40 Even though the drug was 
originally designed to act selectively towards cancer cells, this was not the outcome, as the 
overexpressed phosphoamidase in cancer cells did not selectively react to form the intended 
nitrogen mustard. Evidence indicates the prodrug is converted by the hepatic cytochrome P-450 to 
form 4-hydroxycyclophosphamide.40 At this stage the opened ring tautomer of 4-
hydroxycyclophosphamide may form into both carboxyphosphamide (inactive) and the 
phosphoramide mustard (active) by aldehyde dehydrogenase and β-elimination respectively 





Figure 1-7. Metabolic conversion of the prodrug cyclophosphamide to the active phosphoramide 
mustard and the inactive carboxyphosphamide. 
 
1.4 Non-covalent DNA Binders 
1.4.1 Overview 
In addition to the above mentioned anticancer agents like cisplatin which bind to DNA covalently, 
there are also non-covalent binders. Non-covalent DNA binders can be described as intercalating 
or electrostatic binders that bind in major or minor grooves.41 These types of binding interactions 




interactions are important for anticancer treatment, as well as being utilised anti-infective 
medication and numerous other purposes.43  
1.4.2 Groove Binders 
In contrast to the minor groove, few examples of DNA major groove binders have been reported 
in the literature.44 Minor groove binders exhibit a considerable amount of structural diversity, 
contain a topology that approximates the curvature of the DNA minor groove.43 Both distamycin 
and Hoechst 33258 are well known minor groove binders. Distamycin, a naturally occurring 
oligopeptide isolated from Streptomyces species, relies on its crescent shape, amide group N-Hs 
orienting near the minor groove base and the amidine groups which allow for non-covalent 
interactions with DNA, preferentially at A-T rich sequences (Figure 1-8).45 The C-H groups of the 
aromatic pyrrole of distamycin bind with the minor groove of B-DNA with adenine C2-H groups 
as well as though the formation of hydrogen bonds with the adenine NH carboxamide rings and 
the O2 and N3 of adenine and thymidine respectively.46 Groove binding by distamycin is further 
promoted by electrostatic interactions, utilising interactions between the negatively charged 
phosphates of DNA and the positively charged terminus of the ligand.46  
 
Figure 1-8. Minor groove binder distamycin molecular structure (left) and distamycin binding to 





Besides the organic minor groove binders mentioned above, platinum complexes have also been 
investigated. These metal complexes contain both classical minor groove motifs as well as 
intercalating elements. Previously, a cisplatin-distamycin conjugate has been explored, where the 
ammonia ligands of cisplatin were replaced by a coordinated distamycin.47 Initial investigations 
of this coordinative conjugate reveal that it binds to similar base pair sequences, however different 
conformational changes were induced, and cross-links are formed at higher efficiencies, indicating 
that the conjugate will exhibit changed biological activity.47 A novel platinum(II) terpyridine-
based complex (Figure 1-9) was confirmed to bind to double stranded DNA within the minor 
groove with a binding affinity in the order of 104 M-1.48 This complex was also reported to produce 
promising selective cytotoxicity profiles towards various cancer cell lines, including the human 
bone osteosarcoma cell line (U2OS), producing an IC50 value of 33 μM.
48  
 
Figure 1-9. Molecular structure of a platinum(II)-based terpyridine minor groove binder. 
 
1.4.3 Intercalators  
Intercalation is the insertion of a planar aromatic molecule between the two base pairs of DNA.49 
Upon binding to the DNA molecule, intercalators prevent the binding of topioisomerase I to DNA 
and/or stabilise the cleaved DNA formed as a result of topioisomerase II.50 Consequently DNA 
replication is inhibited, resulting in cancer cell death.50 Doxorubicin (Figure 1-10) is one of the 




occurring antibiotic isolated from Streptomyces peucetius.51 Two mechanisms are proposed to 
explain doxorubicins anticancer activity: intercalation and the following inhibition of 
topioisomerase-II-mediated DNA repair and also oxidative stress caused to DNA, proteins and 
cellular membranes, which ultimately leads to apoptosis.52, 53 
A number of different platinum(II) metallointercalators have been investigated containing 1,10-
phenanthroline derivatives as an intercalating ligands and an ancillary ligand consisting of either 
1,2-diaminocyclohexane or 1,2-diaminoethane.54, 55 In particular, and [(5,6-dimethyl-1,10-
phenanthroline)(1S,2S-diaminocyclohexane)platinum(II)]2+ (56MESS, Figure 1-10) has gained 
much attention due to its unique cytotoxic profile, showing a 160-fold greater biological activity 
than cisplatin in certain cancer cell lines (Figure 1-11 & Table 1-1) such as cisplatin resistant 
mouse leukaemia (L1210cisR).56  
 





Figure 1-11. Graph showing the IC50 values (μM) of 56MESS (blue) compared to cisplatin 
(orange) in several cisplatin-resistant cancer cell lines. Data originates from Krause-Heuer et 
al.57 and Moretto et al.58. 
Table 1-1.  IC50 values (μM) of 56MESS compared to cisplatin in several cisplatin-resistant 
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Cell line 56MESS Cisplatin 
5637 (human bladder cancer) 82 ± 29 350 ± 100 
RT-4 (urinary bladder transitional cell) 59 ± 10 1610 ± 161 
LCLC-103H (human lung cancer) 46 ± 13 900 ± 190 
DAN-G (human pancreatic cancer) 40 ± 3 730 ± 340 
MCF-7 (human breast cancer) 28 ± 4 1380 ± 290 
A427 (human lung cancer) 21 ± 12 1969 ± 540 
IGROV1 (human ovarian cancer) 3.4 ± 1 10.6 ± 1.1 
HCT8 (human colon cancer) 2.5 ± 0.4 23.1 ± 2.5 







1.5 Structures of DNA 
Understanding the complicated nature and structure of the DNA molecule as the carrier of inherited 
information is one of the major challenges of modern science. It has been almost 70 years since 
Watson and Crick released the classical paper describing the major model of the structure of 
DNA.59, 60 Within it they describe the canonical right-handed double-helical B-form of DNA, 
containing of two complementary DNA strands arranged as a double helix which relies on 
hydrogen bonding between base pairs of the two chains, with adenine and thymine forming two 
bonds, while cytosine and guanine form three bonds.61 The structure is further stabilised by 
hydrophobic interactions between the heterocyclic rings of bases which stack on top of each 
other.62  
Based on diffraction studies, B-DNA (Figure 1-12) is only an average conformation of DNA and 
there is usually not enough room in the nucleus for the DNA molecule to unwind itself in a perfect 
linear B-DNA form. Other well-known DNA structures include both Z-DNA and A-DNA (Figure 
1-12). Z-DNA is a left-handed duplex in certain dinucleotide repeats such as CpG and GpC 
sequences.63 Under normal cellular conditions, Z-DNA is thermodynamically unfavourable, with 
the exception of the cases of high salt concentrations or negative supercoiling, however the exact 
mechanism between the transition from B-DNA to Z-DNA remains unclear.63 Another well-
known DNA structure is A-DNA (Figure 1-12), which consists of a stubby, wide helix with canted 
bases in relation to the helix.64 Also, A-DNA contains a vast major groove and slight minor 
groove.64 
 





Other lesser known DNA conformations include cruciform DNA, hairpin DNA the DNA bubble 
(Figure 1-13). The cruciform conformation forms when interstrand base pairing converts to 
intrastand base pairing with inverted repeats.65 Hairpin DNA also occurs in inverted repeats or 
palindromes.66 Hairpin DNA is known to regulate several of cellular process, including 
transcription, recombination and gene expression.62 DNA bulges occur in double stranded DNA 
due to unpaired nucleotides on one of the two strands, resulting in a bulged duplex.62 DNA bubbles 
are crucial for DNA condensation which act by releasing the bending energy of the bent DNA 
duplex, improving the folding process of DNA around histones.67 Many more DNA conformations 
are also possible such as the i-motif, quadruplex, triplex together with countless others.62 
 
Figure 1-13. Structure of hairpin DNA and a DNA bulge. Images rendered using UCSF 
Chimera.  
 
1.6 G-Quadruplex DNA: A Potential Anticancer Target 
The search for improved anticancer agents has recently focused specifically on the telomeric 
regions found at the end of chromosomes.  The telomere has a number of significant roles within 
the cell, including protecting DNA from interchromosomal fusion, recombination and nucleolytic 
shortening.68, 69 Yet, the primary and most important function of the telomere is the protection of 




amount of telomeric DNA is lost with each cell division. Therefore, the telomere has a vital role 
of protecting the cells genes from deterioration due to the end replication problem. Once the 
telomere reaches critical length, the cell undergoes apoptosis or senescence.69 On the contrary, 85-
90% of cancer cells prevent telomeric shortening by the action of an overexpressed enzyme known 
as telomerase.70 Telomerase extends telomeric length by adding d(TTAGGG) repeats, allowing 
the cancer cells to divide uncontrollably, leading to some scientists describing these cells as 
“immortal”.70 With the exception of proliferation of renewal tissue, telomerase remains undetected 
in ordinary somatic cells.71 Even if telomerase is expressed in ordinary somatic cells, the overall 
trend is telomere shortening over time, as it is only expressed in small quantities in these cells.71 
Since telomerase can be found most exclusively in cancer cells, telomerase has received much 
attention as a potential selective anticancer target.  
The telomere consists of repeated nucleotides of the sequence TTAGGG (with a complementary 
TCCCAA sequence), as well as a single-stranded overhang of the repeated sequence TTAGGG.72 
Sequences abundant in guanine within the 3′ overhang are known to form structures known as G-
tetrads (Figure 1-14), which form owing to hydrogen bonds formed between the Watson-Crick 
edge of one guanine base and the Hoogsteen edge of a neighbouring guanine base, which is further 
stabilised by a metal cation which forms electrostatic interactions with the carbonyl groups of 
guanine.70, 71 The self-assembly of these G-tetrads results in the formation of G-Quadruplex DNA 
(G4-DNA), which forms as a result of π-stacking interactions (Figure 1-14).
73 G4-DNA is also 
capable of forming a variety of topologies such as monomolecular parallel quadruplexes with 
propeller loops (e.g. PBD ID: 1XAV (Figure 1-14) and 1KF1),74, 75 bimolecular quadruplexes with 





Figure 1-14. Hoogsteen base pairing in a G4-DNA tetrad (left) and a G4-DNA structure from the 
Protein data bank, 1XAV (right). 
 
Telomerase requires its own RNA template to hybridise with the 3′ overhang in order to generate 
additional d(TTAGGG) repeats.73 Therefore, the stabilisation and the prevention of unfolding of 
the G-Quadruplex structure will inhibit telomerase, as its RNA template will be prevented from 
hybridising with the 3′ overhang. Numerous G4-DNA stabilisers have been reported, including 
synthetic inorganic metal complexes and organic compounds, as well as naturally occurring 
compounds. Metal complexes have gained attention as they offer advantages over their organic 
counterparts. Firstly, the metal centre is capable of arranging ligands in a square planar 
conformation which is ideal for G4-DNA binding via π-stacking interactions.
73 Furthermore, the 
presence of a metal atom withdraws electrons from aromatic ligands, allowing for stronger binding 
with G4-DNA.
73 The positive charge of a cationic metal allows for further interactions with the 
grooves and negatively charged phosphates of the G4-DNA structure and allows for the positioning 
of the stabilising molecule in the middle of the G4-DNA structure, which would normally be 
occupied by a metal ion such as potassium or sodium.73  
Ma et al. have reported a platinum(II) complex consisting of dipyridophenazine (dppz) based 
ligands, which displays a nanomolar anti-telomerase activity, which is one of the most potent 




used, with a potent example investigated by Terenzi et al., a nickel complex exhibiting a 100-fold 
selectivity towards G4-DNA over B-DNA (Figure 1-15).
79 Telomestatin (Figure 1-15), a naturally 
occurring molecule produced in the bacterial species Streptomyces anulatus, has shown success in 
stabilising G4-DNA, and is the only G4-DNA stabiliser to have entered clinical trials.
80 
Unfortunately, telomestatin is not viable, as the lack of efficient synthetic and purification methods 
prevent its wider use.81 
In addition to telomeric regions, G4-DNA can be found in other areas of the human genome, in 
particular the human oncogene promoter regions. These promoter regions regulate the 
transcription of corresponding oncogenes and play a significant role in the pathogenesis of certain 
cancers.  Ligands which bind to the G-Quadruplex structure in telomeric sequences have been 
shown to bind to the same structure in oncogene promoter regions such as c-myc, bcl-2 and c-kit.82 
For example, c-myc overexpression plays an oncogenic role in the formation of many tumours, 
most notably Burkitt lymphoma.83 The overexpression of c-myc results in metabolic changes 
which are associated with the tumours increased need for proteins, lipids and nucleic acids, all of 
which are required for rapid cellular proliferation.83 C-kit, in contrast, is normally overexpressed 
in mast, melanocytic, haematopoietic stem and interstitial cells.84 Specific mutations, deregulation 
and overexpression of c-kit has been detected in several human cancers, including leukaemia, and 





   
  
Figure 1-15. Molecular structure of [Pt(11-carboxydipyrido[3,2-a:2′,3′-c]phenazine)(2-
phenylpyridine)]2+ (12), [Ni(N,N'-bis-5-(triethyl ammonium methyl)-salicylidene-2,3-
Naphthalendiimine)]2+ (13) and Telomestatin (14).  
 
1.7 The i-Motif Secondary DNA Structure 
Within genomic DNA, whenever a guanine is present there is normally a cytosine on the 




quadruplex structures are also rich in cytosine on the complementary strand and such cytosine rich 
sequences are also capable of forming a similar folded structure known as the i-motif (Figure 1-
16).82, 86 These structures and have been extensively researched due to their applications in 
nanotechnology.86 
The i-motif secondary DNA structure has been largely ignored in the design of G-Quadruplex 
stabilisers due to the misconception that the hemi-protonated cytosine+-cytosine base pairs found 
within the core of the i-motif require acidic pH to form.87 As a result, the i-motif was thought to 
be biologically irrelevant as it was believed that this structure is unstable under physiological pH.82 
On the contrary, more recent evidence suggests that that the i-motif structure can be stabilised at 
neutral pH.87 A recent study published in 2019 by Waller et al. has demonstrated that ligands which 
are traditionally thought of as G-Quadruplex stabilisers (e.g. BRACO-19 and Berberine) also 
interact with the i-motif structure at neutral pH, highlighting the biological importance of taking 
into consideration of the i-motif in drug design.88 The incorporation of a transitional metal within 
molecules that stabilise G4-DNA could improve selectivity and binding affinity towards G4-
DNA.89 A previous study by Shi et al. has reported ruthenium complexes with a strong preference 
for G4-DNA over the i-motif.
90 
 




1.8 Experimental Methodologies  
1.8.1 Nuclear Magnetic Resonance Spectroscopy  
Owing to its versatile nature, nuclear magnetic resonance (NMR) spectroscopy is an extensively 
used spectroscopic technique with a variety of purposes in many chemical disciplines, including 
organic, inorganic and biological chemistry. The main purposes of NMR in chemistry includes the 
determination of a compounds molecular structure, the assessment of purity of a chemical product 
and reaction monitoring. NMR can be divided into continuous wave (CW) NMR, as well as pulsed 
Fourier transform (FT) NMR.91 FT spectrometers use a frequency width in the range of 1-10 μm, 
which is able to excite all nuclei in all local environments at once. A routine FT NMR experiment 
involves the exposure of atomic nuclei to a homogenous magnetic field and a radio frequency (rf) 
pulse.92 In order to obtain a signal of greatest intensity, a 90o pulse may be used, which rotates the 
magnetisation from the z axis to the xy axis. The probe coil then detects the induced signal which 
originated as a result of the magnetisation rotating along the xy axis.  Within a few seconds, the 
signal decays to zero and produces a Frequency Induction Decay (FID). The FID, a time domain, 
is then converted to a frequency domain by a process known as FT and after phase corrections 
results in an NMR spectrum.  
Electronegative atoms withdraw electron density from neighbouring atoms and as a result of these 
inductive effects, neighbouring atoms are said to be deshielded. Atoms that are deshielded produce 
signals at a higher chemical shift and are said to be downfield since they are influenced more 
strongly by the external magnetic field. The modified Larmor frequency equation (Equation 1.1) 
indicates that the field strength is related to the resolution of the spectra obtained. The Larmor 
equation is given by:  




where ω is the angular frequency, γ is the gyromagnetic ratio (a constant specific for each type of 
nucleus), Bo the magnetic field strength of the external magnetic field and σ the shielding effect 
experienced by the nucleus.  
A number of NMR experiments can be conducted in order to provide characterisation data and 





as those obtaining information 1H and 13C nuclei are used for obtaining the primary structural 
information of a synthesised molecule.92 Information such as chemical shift, number of chemical 
environments, multiplicity and coupling constants provide the most crucial structural information. 
1H nuclei are of particular interest for this purpose due to their ubiquitous nature, high natural 
abundance and high sensitivity.93 Two-dimensional (2D) NMR provide further structural 
information. Methods such as correlation spectroscopy (COSY) and nuclear Overhauser effect 
spectroscopy (NOESY) provide information on spins which are coupled to each other and help 
identify cross relaxation between spins that are spatially close to each other.94, 95 The 195Pt-HMQC 
(Heteronuclear multiple-quantum correlation spectroscopy) is also important for characterising 
platinum complexes, confirming whether ligands have coordinated to the platinum centre through 
the identification of through bond correlations.96 
1.8.2 Ultraviolet-Visible Spectroscopy  
Ultraviolet-visible (UV-Vis) spectroscopy is a technique with a variety of different applications 
which works by determining the electronic transitions of a molecule.97, 98 UV-Vis spectroscopy 
relies on bonding and nonbonding electrons absorbing light in the visible and ultraviolet light 
region of the electromagnetic spectrum (200-800 nm).98 However, many molecules investigated 
by UV spectroscopy have been carried out in the range of 190-380 nm, as the majority commercial 
spectrometers are often designed for these specific wavelengths.98 The Beer-Lambert law relates 
the absorbance of light to the material through which it travels and is shown in the equation: 
𝐴 = log (
𝐼𝑜
𝐼
) =  𝜀𝑙𝑐 
where A is the absorbance, Io the intensity of the monochromatic light shone into a solution, I is 
the intensity of the transmitted light, ε is the extinction coefficient (M-1 cm-1) which is 
characteristic for each molecule, l is the length of the solution the light passes through (cm),  and 
c is the concentration of the solution (M).99, 100 The determination of the extinction coefficient is a 
commonly used characterisation step for newly synthesised molecules and allows for further 
testing of molecules such as determining their lipophilicity.  
1.8.3 Electron Spray Ionisation Mass Spectroscopy  
Mass spectroscopy (MS) is an analytical technique used to provide both quantitative (e.g. 





analysed.101 Molecules are first subjected to an ionisation source, where the ions produced then 
travel through the mass analyser where they hit the detector in different areas, depending on their 
mass to charge (m/z) ratio.102  A signal is then obtained to produce a mass spectrum which shows 
the abundance of different signals in relation to their m/z ratio.102 Until the introduction of electron 
spray ionisation mass spectroscopy (ESI-MS) by Fenn et al., only small and volatile compounds 
were able to be analysed by mass spectroscopy as larger molecules could not be converted to the 
gas phase without subsequent degradation and/or fragmentation.103 As a result ESI-MS has 
emerged as a useful way in probing small molecules binding interactions with 
biomacromolecules.104 
The basic design of an ESI-mass spectrometer consists of three basic components (Figure 1-17). 
These components include ion source (which uses electrical energy), the mass analyser and the 
detector.101 The ion optics, the analyser and detector are kept at high vacuum, since ions in the gas 
phase are short lived and quite reactive.101 Mass analysers in an ESI-mass spectrometer can include 
multiple different analysers such as the quadrupole mass analyser, a tandem quadrupole system 
and the ion trap mass analyser.102 Quadrupole mass analysers are most commonly used in clinical 
laboratories due to their versatile nature, small size and are economical compared to other 
analysers.102 The tandem quadrupole system on the other hand allows for a “purification” step 
inside the spectrometer, which then allows the complete avoidance of long and complicated 
purification steps.102 A more recent way to measure ion flux (especially low ion flux) is the use of 
an electron multiplier.101 
 





1.8.4 High Pressure Liquid Chromatography (HPLC) 
HPLC is a type of column chromatography used to characterise synthesised compounds based on 
retention time and to determine the purity of chemical products. An instrument consists of a high 
pressure pump which pumps an analyte and a solvent mobile phase through the column consisting 
of a packed stationary phase.105 The retention time of each chemical species in the analyte is 
determined by how strongly each chemical species interacts with the stationary phase material. As 
a result, chemicals which exhibit little interaction with the stationary phase will elute with the 
solvent the earliest, while chemicals which strongly interact with the stationary phase will elute 
with the solvent the slowest. Many different stationary phases are available, with the most well-
known being reversed phase (an organic stationary phase) and normal phase (a polar stationary 
phase).106 Mobile phases for HPLC can also be quite varied, but reversed phase HPLC often entails 
the use of either a water to methanol/acetonitrile gradient or isocratic elution. Once the eluted 
chemical species exit the column, they are detected by a detector such as a UV detector.105 
1.8.5 Circular Dichroism (CD) Spectroscopy 
CD is a type of absorption spectroscopy method which relies on the difference in absorption 
between right- and left-handed circularly polarised light.107 CD spectroscopy has many different 
applications, including determining the purity of chiral molecules, determining protein structures 
(e.g. secondary and tertiary structures), assessing thermal stability of molecules and the analysis 
of nanostructures.107, 108 CD spectroscopy is not only fast and inexpensive, but is also extremely 
sensitive, which allows for the analysis of samples with low solubility such as long G-rich DNA 
fragments, making it useful for studying G4-DNA.
107 Limitations may arise from choice of solvents 
as well as ions absorbing in the UV region. Non-absorbing buffers need to be used to allow 
measurement to occur in the far-UV region (<200 nm).  
1.8.6 In Silico Evaluation of Potential Drug Candidates 
Traditionally, the discovery of novel drugs had been achieved through multiple interdisciplinary 
fields such as pharmacology and chemistry which are time consuming and expensive processes.109 
More recently with the advent of computational technology, drug discovery has been profoundly 
changed in order to evaluate drugs more rapidly and economically.110 Docking is a form of 
computational research which attempts to predict the binding mode and affinity of ligands towards 




candidates, resulting in rational decisions in drug design, including the identification of a 
biomolecular target, the selection of a lead compound with the best binding affinity and the 
optimisation of pharmacokinetic and pharmacodynamics characteristics of the potential drug.110, 
111 
Autodock Vina is a very popular free open source molecular docking program developed by The 
Scripps Research Institute.112 This software predicts the different conformations of ligands towards 
their substrate as well as the free binding energy between them. Additionally, Vina was designed 
to use PDBQT files, an extension of the PDB file format, allowing substrate NMR and x-ray 
crystallography structures to be easily obtained and utilised.  Vina utilises an efficient optimisation 
algorithm and can run calculations in parallel in order to accelerate computation. However, the 
vina scoring function is only approximate, including implicit hydrogens, spherically symmetric 
hydrogen bond potentials and no ionic contribution. 
1.8.7 The MTT Cell Viability Assay 
To assess the anticancer effect of a newly synthesised compound, a variety of methods may be 
used to assess a compounds cytotoxicity towards the hosts cells. Among the many different assays 
available, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) bioassay 
remains the one of the most commonly used assays that has long been regarded as the gold standard 
of cytotoxicity testing.113 The MTT bioassay is based on the concept that for most viable cells 
mitochondrial activity remains constant, meaning that the amount of mitochondrial activity is 
linearly related to the amount of viable cells present.114 Mitochondrial activity of viable cells is 
determined based on the conversion of MTT into the purple coloured formazan product (Figure 1-
18), which is measured using absorbance at 570 nm.114 Despite being the gold standard for 
cytotoxicity testing, the MTT bioassay is not without drawbacks. The formation of formazan 
crystals is dependent on metabolic rate and the amount of mitochondria in the cell, resulting in 
many known interferences.113 Additionally, the MTT bioassay requires numerous wash steps, 




Figure 1-18. The conversion of MTT to the purple coloured product Formazan in the 
mitochondria. 
 
1.9 Project Aims 
The aim of this project was to develop asymmetric platinum(II)-based anticancer complexes 
incorporating two planar aromatic ligands, being either 1,10-phenantrholine-based or  2,2'-
bipyridine-based (Figure 1-19). The rationale for this strategy involves quantitative structure 
activity relationships which reveal that a large aromatic surface area will facilitate π-π stacking 
with G4-DNA. In particular, 3,4,7,8-tetramethyl-1,10-phenathroline (Me4phen) was chosen to 
form part of most proposed complexes (Figure 1-19) because [Pt(Me4phen)2]
2+ was reported to 
demonstrate a promising cytotoxicity profile against certain cancer cell lines  as well as strong 
binding affinity towards G4-DNA.
115 Furthermore, in silico studies reveal that this complex 
exhibits a strong binding affinity towards G4-DNA and a low binding affinity towards dsDNA, 
suggesting that Me4phen plays a role in selectively towards G4-DNA. It was proposed that these 
platinum-based complexes will be synthesised and characterised (using HPLC, NMR, UV and 
ESI-MS), before undergoing binding studies (using ESI-MS and CD spectroscopy), docking 
























2. Synthesis and 














Potassium tetrachloroplatinate (K2PtCl4) was purchased from Precious Metals Online. Deuterated 
solvents (i.e. D2O) used for NMR characterisation were purchased from Cambridge Isotope 
Laboratories. 1,10-phenanthroline (Phen), 5,6-dimethyl-1,10-phenanthroline (56Me2phen), 2,2′-
bipyridine (Bpy), 4,4′-dimethyl-2,2′-bipyridine (Me2bpy) and pyrazino[2,3-f][1,10]-
phenanthroline (Dpq) were purchased from Sigma-Aldrich. 4,7-dimethyl-1,10-phenanthroline 
(47Me2phen) and 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4phen) were purchased from Alfa 
Aesar. Methanol was purchased from Honeywell. Acetonitrile was purchased from RCL Labscan. 
Dichloromethane (DCM) and DMSO were purchased from Chem-supply.  
2.2 Instrumentation 
2.2.1 NMR Spectroscopy 
All NMR experiments were performed using a Bruker Avance 400 MHz NMR spectrometer at 
298 K in D2O and referenced internally to the chosen solvent peak. Samples were prepared using 
500 µL of solvent in 5 mm OD NMR tubes. 1H NMR experiments were performed at a spectral 
width of 14 ppm and 16 scans. COSY NMR experiments were performed at a spectral width of 20 
ppm and 2 scans. 1H-195Pt HMQC experiments were performed at a -2300 ppm spectral centre, at 
a spectral width of 2500 in the F1 dimension (195Pt nucleus) as well as a spectral width of 12 ppm 
in the F2 dimension (1H nucleus) with varying scans (see Table 2-1). All NMR spectra acquired 
were processed using Bruker Topspin 4.0 and the following processing parameters were applied: 
automatic phase correction and automatic base line subtraction. Final spectra were annotated using 
Microsoft Powerpoint 2013. All resonances were described in terms of chemical shift (δ, ppm), 
integration, multiplicity and coupling constant. Multiplicity of each resonance were abbreviated 
















2.2.2 UV-Vis Spectroscopy 
UV-Vis spectra of the synthesised products were obtained using a Shimadzu UV-1800 
spectrometer over a range of 200-400 nm. All stock solutions of synthesised products were 
prepared in H2O, titrated into a known volume of solvent and a spectrum was recorded for each 
titration. All spectra obtained were baseline corrected and concentration versus absorbance at 
maximum wavelength peaks was plotted in order to obtain an extinction coefficient (ε). All 
experiments for each synthesised products were repeated three times.  
2.2.3 High Pressure Liquid Chromatography 
HPLC chromatograms of the synthesised products were obtained using an Agilent Technologies 
1260 Infinity HPLC instrument comprised of the following modules: 1260 ALS, 1260 FC-AS, 
1260 TCC, 1260 DAD, a 1260 HIP Degasser and a 1260 Binary Pump. HPLC experiments were 
conducted using a Phenomenx Onyx Monolithic C18 reversed-phase column with a sample 
injection volume of 5 μL. The mobile phase solvents consisted of 0.06% Trifluoroacetic acid 
(TFA) in water (solvent A) and 0.06% TFA in acetonitrile (solvent B). A gradient of either 10-
100%, 0-100% or 10-50% solvent A to solvent B was used at a flow rate of 1 mL min-1 over 15 
minutes.  
2.2.4 High Resolution Mass Spectroscopy 
A high resolution mass spectrum was obtained for all synthesised products using a Waters 
SYNAPT G2-S quadruple time-of-flight (Q-TOF) HDMS set in positive ion mode. The 
spectrometer was calibrated in the range of 200 and 2500 Da using a leucine encephalin lockmass 
and a sodium iodide reference. The parameters used to obtain each spectrum consisted of a cone 











voltage of 50 V, a capillary potential of 2.2 kV and a microchannel plate of 2.2 kV. The desolvation 
gas flow rate was set to 150 L hr-1 at 150 oC with an ionisation source temperature of 110 oC. 
Samples were prepared in millipure water in the concentration range of 2-20 μM. Samples were 
injected using a KD Scientific Model 100 syringe pump at 5 μL min-1. All spectra were processed 
using MassLynx 4.1 and the monoisotopic mass peak was reported for each complex.  
2.3 Synthesis of Potential G-Quadruplex Stabilisers  
2.3.1 Synthesis of the [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] Precursor 
 
[Pt(Me4phen)Cl2] was synthesised using adapted literature methods.
116 3,4,7,8-tetramethyl-1,10-
phenanthroline (~0.08 g, 0.34 mmol) was dissolved in 10 mL of hot DMSO and combined with a 
hot solution of K2PtCl4 (~0.14 g, 0.34 mmol) in 1 mL of water and 3 mL of DMSO. The solution 
was refrigerated at 4 oC for 48 hours until a yellow precipitate formed. This yellow precipitate was 
filtered and washed with DMSO and acetone. [Pt(Me4phen)Cl2] was also synthesised using by 
microwaving 3,4,7,8-tetramethyl-1,10-phenanthroline (~ 0.03 g, 0.13 mmol) with K2PtCl4 (~0.05 




2.3.2 General Synthesis of [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(PL)]Cl2  
 
The yellow precipitate ([Pt(Me4phen)Cl2] (80-90 mg, 0.15 mmol) was then microwaved with 1 
equivalent of a second polyaromatic ligand (PL, where PL = Phen, 56Me2phen, 47Me2phen, Bpy, 
Me2bpy or Dpq) in 20 mL of water at 180 
oC for 1 hour until the reaction mixture became clear. 
The resulting clear yellow solution was lyophilised and the crude yield determined.  
2.3.3 Synthesis of [Pt(5,6-dimethyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2 
 
K2PtCl4 (0.0729 g, 0.2 mmol) was microwaved with 1 equivalent of each ligand (56Me2phen and 
Phen), in 20 mL of water at 180 oC for 1 hour until the reaction mixture became clear.  
2.3.4 Purification of Synthesised Complexes 
Each complex was purified using a Biotage Isolera One purification system and a water to 
methanol gradient (see Table 2-2). The elution of each component was monitored at 214 and 254 




[Pt(Me4phen)(Dpq)]Cl2 required an additional purification step after flash chromatorgraphy. This 
additional purification step involved dissolving the separated component from flash 
chromatography containing the complex in water (20 mL) and by washing with 3 × 15 mL of 
DCM, collecting the water layer.  
Table 2-2. Purification methodology for each complex using the Biotage Isolera One 










































































2.4 Summary of Synthesised Pt(II) Complexes 
2.4.1 [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2 (P4P1) 
 
Yield (26.5 mg, 21 %), 1H NMR δ (D2O): 9.15 (d, 2H, J = 5.49 Hz), 8.67 (d, 2H, J = 8.14 Hz), 
8.63 (s, 2H), 8.17 (s, 2H), 8.06 (s, 2H), 7.70 (dd, 2H, J = 5.74, 8.73 Hz), 2.78 (s, 6H), 2.45 (s, 6H). 
195Pt-1H NMR δ (D2O): -2236.0/9.15, -2236.0/8.63. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 
104, water): 226 (6.27 ± 0.08), 276 (4.18 ± 0.04), 293 (3.26 ± 0.08), 356 (0.61 ± 0.02), 370 (0.68 
± 0.02). HRMS (ESI +ve TOF) m/z: [M]2+ calc for C28H24N4 
195Pt2+: 305.5824 m/z; found: 




Yield (14.0 mg, 25 %), 1H NMR δ (D2O): 9.11 (d, 2H, J = 5.40 Hz), 8.85 (d, 2H, J = 8.50 Hz), 
8.66 (s, 2H), 8.17 (s, 2H), 7.79 (dd, 2H, J = 5.53, 8.31 Hz), 2.77 (s, 6H), 2.76 (s, 6H), 2.47 (s, 6H). 
195Pt-1H NMR δ (D2O): -2272.7/9.11, -2272.7/8.66. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 




+ve TOF) m/z: [M]2+calc for C30H28N4 
195Pt2+: 319.5981 m/z; found: 319.5976 m/z.  RP-HPLC 




Yield (38.1 mg, 28 %), 1H NMR δ (D2O): 8.96 (d, 2H, J = 5.59 Hz), 8.62 (s, 2H), 8.18 (s, 2H), 
8.14 (s, 2H), 7.60 (d, 2H, J = 8.54), 2.86 (s, 6H), 2.76 (s, 6H), 2.44 (s, 6H). 195Pt-1H NMR δ (D2O): 
-2260.7/8.96, -2260.7/8.62. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 104, water): 216 (5.14 ± 
0.06), 224 (5.37 ± 0.07), 275 (3.83 ± 0.05), 300 (2.86 ± 0.03), 360 (0.61 ± 0.02), 377 (0.78 ± 0.02). 
HRMS (ESI +ve TOF) m/z: [M]2+calc for C30H28N4 
195Pt2+: 319.5981 m/z; found: 319.5976 m/z. 
RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, tR 12.265 min.  
2.4.4 [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(4,4′-dimethyl-2,2′-bipyridine)]Cl2 (P4B2) 
 
Yield (34.9 mg, 46 %), 1H NMR δ (D2O): 8.61 (d, 2H, J = 6.33 Hz), 8.58 (s, 2H), 8.22 (s, 2H), 
8.02 (s, 2H), 7.47 (d, 2H, J = 5.64 Hz), 2.78 (s, 6H), 2.59 (s, 6H), 2.46 (s, 6H).  195Pt-1H NMR δ 
(D2O): -2243.3/8.61, -2243.3/8.58. Electronic spectrum: λmax nm (ε/M




(3.26 ± 0.02), 222 (3.32 ± 0.03), 233 (3.40 ± 0.03), 288 (2.46 ± 0.02), 320 (1.46 ± 0.01), 352 (0.50 
± 0.01), 370 (0.43 ± 0.01). HRMS (ESI +ve TOF) m/z: [M]2+calc for C28H28N4 
195Pt2+: 307.5981 
m/z; found: 307.5922 m/z. RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, 
tR 7.102 min. RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, tR 7.102 min.  
2.4.5 [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(2,2′-bipyridine)]Cl2 (P4B1) 
 
Yield (26.4 mg, 24 %), 1H NMR δ (D2O): 8.86 (d, 2H, J = 5.68 Hz), 8.67 (s, 2H), 8.39 (t, 2H), 
8.29 (d, 2H, J = 7.93), 8.22 (s, 2H), 7.72 (t, 2H), 2.79 (s, 6H), 2.51 (s, 6H). 195Pt-1H NMR δ (D2O): 
-2249.6/8.86, -2249.6/8.67. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 104, water):  210 (3.23 ± 
0.04), 222 (3.52 ± 0.04), 232 (3.63 ± 0.07), 287 (2.73 ± 0.07), 315 (1.66 ± 0.07), 352 (0.57 ± 0.06), 
370 (0.50 ± 0.05). HRMS (ESI +ve TOF) m/z: [M]2+calc for C26H24N4 
195Pt2+: 293.5824 m/z; 
found: 293.5833 m/z. RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, tR 







Yield (25.1 mg, 24 %), 1H NMR δ (D2O): 9.53 (d, 2H, J = 8.04 Hz), 9.40 (d, 2H, J = 5.13 Hz), 
9.32 (s, 2H), 8.76 (s, 2H), 8.12 (dd, 2H, J = 5.15, 8.05 Hz), 8.05 (s, 2H), 2.71 (s, 6H), 2.54 (s, 6H). 
195Pt-1H NMR δ (D2O): -2238.1/9.32, -2238.1/8.76. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 
104, water): 208 (4.09 ± 0.01), 223 (4.33 ± 0.03), 261 (4.26 ± 0.03), 290 (3.82 ± 0.03), 355 (0.69 
± 0.02), 374 (0.70 ± 0.02). HRMS (ESI +ve TOF) m/z: [M]2+calc for C30H24N6 
195Pt2+: 331.5855 
m/z; found: 331.5865 m/z. RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, 
tR 7.102 min. RP-HPLC Phenomenex C18 150 × 4.6 mm, 10 – 50% B over 15 min, tR 11.045 min.  
2.4.7 [Pt (5,6-dimethyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2 (P3P1) 
 
Yield (18.1 mg, 16 %), 1H NMR δ (D2O): 9.15 (d, 2H, J = 5.44 Hz), 9.12 (d, 2H, J = 5.40 Hz), 
8.85 (d, 2H, J = 8.43 Hz), 8.79 (d, 2H, J = 8.11 Hz), 8.12 (s, 2H), 7.88 (m, 4H), 2.75 (s, 6H). 195Pt-
1H NMR δ (D2O): −2283.1/9.15, -2283.1/9.12 ppm. Electronic spectrum: λmax nm (ε/M
-1 cm-1 × 
104, water): 227 (6.55 ± 0.04), 279 (4.26 ± 0.02), 290 (3.54 ± 0.02), 352 (0.49 ± 0.01), 373 (0.56 
± 0.01). HRMS (ESI +ve TOF) m/z: [M]2+calc for C26H20N4 
195Pt2+: 291.5668; found: 291.5671 
m/z.  RP-HPLC Phenomenex C18 150 × 4.6 mm, 0 – 100% B over 15 min, tR 7.161 min.  
2.5 Results and Discussion  
2.5.1 Synthesis of the [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] Precursor 
The first step towards synthesising the desired G-Quadruplex stabilisers is to coordinate the first 
polyaromatic ligand (Me4phen) to the platinum of K2PtCl4. [Pt(Me4phen)Cl2] was initially 
synthesised according to previously established methods described by McFadyen et al. and the 
yield obtained is greater (83%) in comparison to the reported yield (71%). McFadyen et al. have 
previously allowed the reaction mixture to cool, upon which the yellow [Pt(Me4phen)Cl2] complex 
crystallised (Figure 2-1). In order to improve upon this, the reaction mixture was refrigerated at 4 
oC over a period of 2 days in order to facilitate crystallisation of the desired [Pt(Me4phen)Cl2]  




of the solution, Figure 2-1) was precipitated by adding water as required, leading to the 
precipitation of any remaining product which would otherwise become discarded in the filtration 
process.  
 
Figure 2-1. Photograph of the synthesis of [Pt(Me4phen)Cl2] according to the method described 
by McFadyen et al.. Left: A heated solution of K2PtCl4 and Me4phen. Right: The crystallised 
[Pt(Me4phen)Cl2] product.  
 
Furthermore, with the intention of reducing the amount of time needed to obtain the 
[Pt(Me4phen)Cl2] complex, a microwave method was developed. The method involves 
microwaving the K2PtCl4 and Me4phen in water for 15 minutes at 120 
oC, upon which a yellow 
solid forms. Even though the microwave method is much more time efficient than the DMSO 
method, the yield is much lower (56% compared to 83%). The most apparent reason for the 
decreased yield is that the product was not allowed to crystallise over time, resulting in a very fine 
solid which is difficult to collect via vacuum filtration (see Figure 2-2), even when using a 
membrane filter. Initial filtering of the fine solid product resulted in a yield of only 52%, while 
filtering a second time only increases the yield to 56%, with much of the product still remaining 
in the filtrate. In order to obtain a higher yield using the microwave method, large amounts of 
DMSO and acetone are required to wash the collected product with multiple filtration steps. As a 
result, the microwave method was considerably inefficient in terms of the amount of time and 





Figure 2-2. Photograph of the synthesised [Pt(Me4phen)Cl2] using a microwave reactor. 
 
2.5.2 Synthesis of [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(PL)]2+ and [Pt(5,6-dimethyl-
1,10-phenanthroline)(1,10-phenantrholine)]2+ 
As with the synthesis of [Pt(Me4phen)Cl2], the synthesis of [Pt(Me4phen)(PL)]
2+ and 
[Pt(56Me2phen)(Phen)]
2+ complexes underwent major method modifications, with the end result 
being the development of a fast method with yield improvements. The main issue that needed to 
be addressed is the insoluble nature of the starting material [Pt(Me4phen)Cl2], in all laboratory 
solvents (Figure 2-3). Instead of using water to reflux the reaction, a 50:50 mixture of ethylene 
glycol and water was used and the product precipitated by a PF6
- counterion exchange, based on 
previously reported methods.117 The addition of ethylene glycol to water (50%) allowed higher 
reflux temperatures (~120 oC) and improved solubility of the [Pt(Me4phen)Cl2]. However, the 
reaction time was very long and produced very low yields (< 10%). The method was especially 





Figure 2-3. Photograph of a reflux reaction setup, showing the yellow insoluble 
[Pt(Me4phen)Cl2] complex. 
 
Because refluxing in a mixture of ethylene glycol and water at 120 oC was not particularly 
successful due to insolubility, an alternative method was explored. Alexander et al. successfully 
coordinated 2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline) to [Pt(Bpy)Cl2] in N,N-
dimethylformamide (DMF), where the product was precipitated by the addition of excess water to 
the reaction mixture with potassium hexafluorophosphate. In order to test the efficacy of using 
DMF as a reflux solvent, Me2bpy was used for coordination to [Pt(Me2bpy)Cl2] to form 
[Pt(Me2bpy)2](PF6)2 using DMF and compared to using a 50:50 mixture of ethylene glycol and 
water. While both reagents were completely soluble in DMF at room temperature, the coordination 
of the ligand was slow and incomplete, producing a very impure crude product (see Figure 2-4). 
Refluxing in a 50:50 mixture of ethylene glycol and water produced a pure crude product in a 
much shorter time period (see Figure 2-4). Even though DMF did solve solubility issues, it did not 







Figure 2-4. 1H NMR spectrum of the crude product [Pt(Me2bpy)2](PF6)2 obtained from refluxing 




Although ethylene glycol and water reaction mixtures were suitable for some reactions, it was not 
suitable for more insoluble ligands such as Dpq. For this reason, the use of a microwave reactor 
was explored that led to major improvements. Previous reports indicate that a microwave reactor 
could reduce the required time to coordinate and help increase percentage yield.118 Figure 2-5 
shows the HPLC chromatogram of the crude reaction mixture for the formation of complex P4P1 
(from 0.04 mmol [Pt(Me4phen)Cl2] and 1 equivalent of Phen) at various temperatures in 7 mL of 
water, where the reaction time was 1 hour.  It was observed that the optimal reaction conditions 
occurred at 180 oC with a reaction time of 1 hour (Figure 2-5). Under these reaction conditions the 
yield increased considerably to 20-30% for most complexes, when compared to refluxing in a 
50:50 mixture of ethylene glycol and water which produced yields < 10%. The main factor 
contributing to reduced yields with the microwave method was the formation of unwanted by-
products, such as symmetric platinum(II)-based complexes in the form of [Pt(Phen)2]
2+ and 
[Pt(Bpy)2]
2+ (where Phen and Bpy represent 1,10-phenanthroline and 2,2′-bipyridine based 
ligands). For example, when microwaving [Pt(Me4phen)Cl2] with Me2bpy, both [Pt(Me4phen)2]
2+ 
and [PtMe2bpy)2]
2+ form as by-products in addition to the desired asymmetric complex 
[Pt(Me4phen)(Me2bpy)]
2+ (P4B2) (Figure 2-6). It was also found that microwaving K2PtCl4 with 
two polyaromatic ligands essentially makes no difference in the ratios between the symmetric 
complexes and the asymmetric complex, as seen with the synthesis of [Pt(56Me2phen)(Phen)]Cl2 
(P3P1). This suggests that the asymmetric complex and the symmetric complexes are at 
equilibrium at high temperatures. Consequently, in order to increase the yield of the asymmetric 
complexes, the symmetrical complexes separated using flash chromatography can be reacted 
together to form the asymmetric complex in the same ratios as before, however this process 
requires the use of valuable time and further resources. An increased yield was achieved by 
reacting the symmetric complexes [Pt(Me4phen)2]Cl2 and [Pt(47Me2phen)]Cl2) to form 
[Pt(Me4phen)(47Me2phen)]Cl2, increasing the yield from 28% to 40%. In summary, the use of a 
microwave reactor greatly improved reaction yields for G-Quadruplex stabilisers, which was not 





Figure 2-5. HPLC chromatograms of the crude reaction mixture for the synthesis of P4P1 from 






Figure 2-6. An example HPLC chromatogram showing the crude reaction mixture for the 
synthesis of P4B2 using a microwave reactor (left) and a photograph showing the reaction 
mixture containing the three water soluble products (right).  
 
2.5.3 Characterisation of [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)(PL)]Cl2 complexes 
and [Pt(5,6-dimethyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2 
A wide range of techniques were used to confirm the successful synthesis of the proposed G-
quadruplex stabilisers, including NMR (1H, COSY and 195Pt-HMQC experiments) and HR-MS. 
NOESY NMR was also utilised to help solve assignment ambiguities. In addition to this, HPLC 
was used to assess purity and to determine the characteristic retention time of each compound. 
UV-Vis spectroscopy was also used to provide a characteristic extinction coefficient for each 
compound which can be utilised for different uses such as determining complex concentration 
during DNA binding studies and studying lipophilicity.  
NMR spectra for each complex was obtained in D2O. 
1H NMR spectra for all complexes were easy 
to assign, except for P4B1. An interesting characteristic was observed for P4B1, where the 
expected doublet of doublets appeared as triplets in D2O, even though the 
195Pt-HMQC spectrum 
for this compound indicated the successful coordination of both ligands (Me4phen and Bpy). It 
was suspected that π-stacking was the cause of this property, as an aqueous environment would 
promote such interactions, as reported for a similar complex, [Pt(Bpy)2](NO3)2.
115 For this reason, 




to be from the uncoordinated Bpy ligand as the complex was degrading in DMSO (see Figure 2-
7). It was found that by lowering the concentration of the NMR sample to 0.06 M the doublet of 
doublets became to be visible, suggesting that π-stacking interactions were be responsible for the 
observed triplets. Unfortunately, diluting the NMR sample caused other peaks to overlap, making 
the 1H assignment not possible. The COSY NMR spectrum was as expected, showing all the 
expected coupling patterns and allowed the unambiguous assignment of protons.  
 
Figure 2-7. 1H NMR spectrum of Bpy (red) and the P4B1 breakdown products (blue). Solvent: 
DMSO-d6. Number of accumulations: 16.  
 
Other than P4B1, all other synthesised complexes followed a straightforward NMR assignment. 
NMR analysis of each complex consisted of the use of 1H, COSY (to identify coupling between 
different protons) and 195Pt-HMQC NMR (to confirm successful coordination of each of the two 
ligands). All complexes exhibit one plane of symmetry which simplified the peak assignment 
process. An example of a 1H NMR spectrum of complex P4P3 can be seen in Figure 2-8. The most 
obvious resonance is the doublet of doublets at 7.79 ppm (J = 5.53, 8.31 Hz), which could only 
correspond to H3/8. The two doublets must therefore belong to either H2/9 or H4/7. These two 
protons can be easily distinguished based on their characteristic and expected coupling constants 




belong to H2/9 due to characteristic coupling constant of 5.40 Hz, while the doublet at 8.85 ppm 
must belong to H4/7, due to its coupling constant of 8.50 Hz. The remaining two singlets in the 
aromatic region belong to either H2′/9′ or H5′/6′, the only two aromatic protons of the Me4phen 
ligand. These can be easily distinguished from their expected chemical shift, with H2′/9′ being 
more deshielded due to its close proximity to the coordinating nitrogen atom and the platinum 
centre.  Therefore the singlet at 8.66 ppm corresponds to H2′/9′, while the singlet at 8.17 ppm 
corresponds to H5′/6. The assignment of H2′/9′ and H5′/6′ is also further confirmed by the 1H 
NMR of P4P2, where the two close singlets (from the H5/6 and H5′/6′) appear upfield in relation 
to H2′/9′, which appears more downfield. In the methyl region, Me4′/7′ and Me4/7 both resonate 
close together at 2.86 and 2.77 ppm, respectively, while Me3′/8′ appears at 2.47 ppm.  
As to further confirm the assignment of protons H5/6 and H5′/6′ in complexes such as P4P1 and 
P4P2, NOESY NMR was employed. An example of an NOESY NMR spectrum for complex P4P1 
can be seen in Figure 2-9. The singlet at ~ 8.12 ppm exhibits long-range coupling towards the 
singlet in the aliphatic region of the NMR spectrum. This confirms that the singlet at ~8.12 ppm 
belongs to proton H5′/6′ as this proton is expected to couple to a methyl group (i.e. Me4′/7′). 
Furthermore, this also confirms that proton H5′/6′ will resonate at a higher chemical shift in 
relation to the H5/6 protons positioned on the Phen and 47Me2phen ligands.  
 
Figure 2-8. 1H NMR spectrum of complex P4P3. Solvent: D2O, Number of accumulations: 16. 





Figure 2-9. NOESY NMR spectrum of complex P4P1, showing long-range coupling between 
protons H5′/6′ and the Me4′/7 group.  
 
COSY NMR was used to confirm correlations between neighbouring protons as seen in the 1H 
NMR assignments. All COSY NMR spectra were in agreement with the 1H NMR spectra. An 
example of a COSY NMR spectrum of complex P4P3 can be seen in Figure 2-10. The expected 
coupling can be seen in this spectrum, with the H3 proton of the 56Me2phen ligand coupling to 
protons H2/9 and H4/7. As with the COSY spectra for other metal complexes, long range coupling 






Figure 2-10. COSY NMR spectrum of complex P4P3, showing the expected correlations of 
H3/8 and protons H2/9 and H4/7.  
 
195Pt-HMQC experiments were used to confirm the successful coordination of each polyaromatic 
ligand to the platinum centre. Two cross-peaks were identified for all synthesised complexes, 
between the platinum centre and protons in the H2 and H2′ positions. Furthermore, the 
identification of cross-peaks provided further confirmation to the NMR assignments for 1H NMR 
spectra, by identifying H2 and H2′ protons. A characteristic chemical shift for the platinum centre 
was identified to occur in the range of -2200 to -2300 ppm, which is in agreement to what is 
previously reported.115 Experimental difficulties were experienced when trying to obtain a cross-
peak signal during 195Pt-HMQC experiments and 1D platinum NMR signals. Ordinary 
experimental parameters consisting of 8 scans did not allow for the formation of a signal and the 
number of scans needed to be increased substantially to at least 1334 in order to obtain a signal for 
most complexes. This was not the case with previously reported symmetrical platinum(II) 
complexes consisting of 1,10-phenanthroline-based and 2,2′-bipyridine-based ligands, as only 256 




symmetric platinum(II) complexes containing the same ligands as the synthesised asymmetric 
complexes, the asymmetry is like a contributing factor. It is possible that a quadrupole moment 
was the cause, as linewidth broadening results as a consequence of rapid nuclear quadrupole 
relaxation in a quadrupole nucleus. This effect can be seen in the 1D platinum NMR spectrum of 
complex P4P2 in Figure 2-12 in comparison to the symmetric complex [Pt(Me2bpy)2](PF6)2, 
where normal experimental parameters (8 scans) allowed for the a correlation between the Pt and 
H2 nuclei to be detected via a 195Pt-HMQC pulse sequence for the symmetric complex.  
 
Figure 2-11. 195Pt-HMQC NMR spectrum of complex P4P3, showing the expected correlation 
between protons H2/9 and H2′/9′ with the platinum centre. Solvent: D2O, Number of 











UV-Vis spectra were obtained for all synthesised platinum complexes and characteristic molar 
extinction coefficients were determined (Table 2-3). Three replicate UV-Vis titration experiments 
were conducted for each platinum complex so that the standard deviation could be determined 
(Table 2-3). Replicates were repeated until consistent results were obtained with minimum error. 
An example of a UV spectrum of complex P4P1 is shown in Figure 2-13. The synthesised 
complexes exhibited two large peaks at approximately 230 and 280 nm (Figure 2-13), which are 
assigned to ligand-centred absorption bands (π-π* transitions) of the polyaromatic ligands.119 The 
smaller peaks between 350 and 370 nm are also attributed to π-π* transitions of the polyaromatic 
ligands.119 The small peak at approximately 380 nm is present for some complexes and is attributed 
to metal to ligand charge transfers.119 A shoulder at 320 nm is observed for complexes containing 
a 2,2'-bipyridine-based ligand (P4B1 and P4B2) and is due to metal to ligand charge transfer 
transitions.119 These peaks are consistent with previously reported symmetric platinum-based bis-
1,10-phenanthroline and bis-2,2'-bipyridine complexes.115 
Table 2-3. Electronic spectrum data for each synthesised complex.  
Complex Electronic spectrum  
λmax nm (ε/M
-1 cm-1 × 104) 
P4P1 226 (6.27 ± 0.08)  276 (4.18 ± 0.04) 
293 (3.26 ± 0.08) 
356 (0.61 ± 0.02) 
370 (0.68 ± 0.02) 
P4P2 216 (5.14 ± 0.06) 
224 (5.37 ± 0.07)  
275 (3.83 ± 0.05) 
300 (2.86 ± 0.03) 
360 (0.61 ± 0.02) 
377 (0.78 ± 0.02) 
P4P3 216 (5.59 ± 0.16) 
228 (6.27 ± 0.12) 
280 (4.28 ± 0.08) 380 (0.57 ± 0.02) 
P4P6 208 (4.09 ± 0.01) 
223 (4.33 ± 0.03)  
261 (4.26 ± 0.03) 
290 (3.82 ± 0.03) 
355 (0.69 ± 0.02) 
374 (0.70 ± 0.02) 
P3P1 227 (6.55 ± 0.04)  279 (4.26 ± 0.02) 
 290 (3.54 ± 0.02) 
352 (0.49 ± 0.01) 
373 (0.56 ± 0.01) 
P4B1 210 (3.23 ± 0.04) 
222 (3.52 ± 0.04) 
232 (3.63 ± 0.07)  
287 (2.73 ± 0.07) 
315 (1.66 ± 0.07) 
352 (0.57 ± 0.06) 
370 (0.50 ± 0.05) 
P4B2 211 (3.26 ± 0.02) 
222 (3.32 ± 0.03) 
233 (3.40 ± 0.03)  
288 (2.46 ± 0.02) 
320 (1.46 ± 0.01) 
352 (0.50 ± 0.01) 






Figure 2-13.  UV-Vis spectrum and extinction coefficient determination of complex P4P1.  
 
HR-MS was used to confirm the successful synthesis and identity of all synthesised complexes. 
This was achieved by calculating the monoisotopic mass and m/z for each complex and comparing 
these values with the detected peaks during HR-MS experiments. All complexes produced an 
isotopic distribution as expected in the 2+ state with minimum error.  Degradation of the 
synthesised complexes was not observed during experiments as mild conditions consisting of a 
low source temperature and low cone voltage has prevented degradation.  Figure 2-14 shows an 
example of a HR-MS of complex P4P2, which is representative of the isotopic distribution of all 






Figure 2-14. Mass spectrum of complex P4P2 showing the expected isotopic distribution. 
Solvent: ammonium acetate buffer (H2O, 150 mM, pH 7), Lockmass: leucine encephalin, Cone 
































3.1 Biological Testing 
3.1.1 Methodology 
In order to assess the biological activity of the synthesised metal complexes, cell line testing was 
performed according to previously established methods.120 Cell line testing was performed at the 
Calvary Mater Hospital in Waratah, NSW, through an existing collaboration with Dr Jennette 
Sakoff and her research team. Results were obtained as concentration required to inhibit cell 
growth by 50% (IC50). The cell lines tested were colon (HT29), glioblastoma (U87), breast (MCF-
7), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), 
glioblastoma (SJ-G2), pancreas (MIA), ovarian (ADDP, cisplatin resistant A2780 clone) in 
addition to non-tumour breast (MCF). Each platinum complex was prepared as a stock solution in 
DMSO and stored at -20 oC. Tumour cell lines were sustained through the use of Dulbecco’s 
modified Eagle’s medium (DMEM), 10 % foetal bovine serum, 10 mM sodium bicarbonate, 
penicillin (100 IU mL-1), streptomycin (100 μg mL-1) and glutamine (4 mM). In comparison to the 
tumour cell lines, the non-tumour cell lines were cultured in 1:1 DMEM: F12 culture media and 
sustained with 5% inactivated horse serum, penicillin (50 IU mL-1), streptomycin (50 μg mL-1), 
Hepes (20 mM), L-glutamine (2 mM), epidermal growth factor (20 ng mL-1), hydrocortisone (500 
ng mL-1), cholera toxin (100 ng mL-1) and insulin (10 μg mL-1). Cells were plated in duplicate 96 
well plates in a total volume of 150 μL in a density of 2,500-4,000 cells per well. 24 hours after 
plating (day 0), during the logarithmic growth phase, 100 μL with or without the complex being 
tested was added to each well. After 72 hours, inhibitory effects were determined using the MTT 
bioassay, where the absorbance at 540 nm was monitored. An 8 point dose response curve was 
produced from which the IC50 was determined, based on the change between the optical density 
values on day 0 and the end of drug exposure.  
3.1.2 Results and Discussion 
The biological activity of each synthesised metal complex is summarised in Table 3-1 and 
compared with clinically used drugs (cisplatin, carboplatin and oxaliplatin). Each complex exhibits 
comparable or better activity across all cell lines when compared to carboplatin, while oxaliplatin 
generally outperformed the synthesised complexes. The synthesised metal complexes generally 
outperformed cisplatin in certain cancers, while cisplatin outperformed most synthesised metal 




cisplatin in colon (HT29), breast (MCF-7), ovarian (A2780) and pancreatic cancer (MIA) cell 
lines. In contrast, cisplatin exhibited better activity against lung (H460), skin (A431), prostate 
(Du145), neuroblastoma (BE2-C) and glioblastoma (SJ-G2) cancer cell lines.  
In terms the synthesised complexes, no correlation was identified with G4-DNA binding affinity 
and cytotoxicity. In particular, P3P1, even though a poor G4-DNA binder (section 3.2 and 3.3), 
exhibited the best cytotoxicity profile for 8 out of 12 tested cell lines. P3P1 showed a 5-fold greater 
activity for both pancreatic (MIA) and colon (HT29) cell lines, when compared to cisplatin. 
Complex P4P1 showed best activity in 3 out of 12 cancer cell lines, including glioblastoma (U87), 
lung (H460) and prostate cell lines (Du145). P4P1 showed a 3-fold greater activity in pancreatic 
(MIA) cancer cell lines as well as a 4-fold greater activity in colon (HT29) cancer cell lines, when 
compared to cisplatin. Complexes P4P3 and P4P2 also exhibited good activity in ovarian (A2780) 
cancer cell lines. Complexes P4B2, P4B1 and P4P6 exhibited poor activity in almost all cancer 
cell lines. The poor activity of complex P4P6 is in agreement with DNA binding studies (see 
Section 3.2). The results for complexes P4B2 and P4B1 should be observed with caution as these 
complexes are prone to solvolysis due to the DMSO used in this MTT bioassay. Instability of these 
complexes may be due to strained bonds between the nitrogen atoms of the ligands and the 
platinum centre, not being entirely planar in conformation. If left in solution for long (1 day or 
more), an insoluble yellow precipitate forms. This was confirmed to be due to the 2,2′-bipyridine-
based ligand no longer being coordinated to the platinum centre, allowing the formation of 












Table 3-1. Biological activity of the synthesised complexes compared to cisplatin, carboplatin and oxaliplatin. Biological activity is reported as IC50 
(μM) – concentration required to inhibit cell growth by 50%.  
 






HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10A ADDP * 





2.9 ± 0.32 2.6 ± 0.27 6.3 ± 1.5 0.86 ± 0.67 2.4 ± 0.34 2.6 ± 0.20 2.5 ± 0.29 2.1 ± 0.81 2.5 ± 0.32 2.7 ± 0.23 3.1 ± 0.13 2.1 ± 0.23 
P4P2 
3.1 ± 0.70 3.1 ± 0.47 3.8 ± 0.46 1.3 ± 0.72 3.0 ± 0.13 3.0 ± 0.067 2.7 ± 0.23 2.0 ± 0.23 2.6 ± 0.37 3.4 ± 0.32 3.2 ± 0.067 2.9 ± 0.067 
P4P3 
3.2 ± 0.65 2.6 ± 0.60 4.9 ± 0.65 0.50 ± 0.36 2.9 ± 0.45 3.3 ± 0.65 2.7 ± 0.45 1.6 ± 0.25 2.8 ± 0.95 2.8 ± 0.45 4.1 ± 0.75 2.8 ± 0.70 
P3P1 
2.5 ± 0.67 5.7 ± 3.2 3.8 ± 1.3 1.0 ± 1.0 3.6 ± 2.4 1.9 ± 0.81 4.5 ± 3.0 0.78 ± 0.56 1.8 ± 1.1 1.5 ± 0.71 1.0 ± 0.42 1.1 ± 0.637 
P4P6 
19 ± 0.67 27 ± 0.33 26 ± 3.0 5.1 ± 4.0 14 ± 2.2 16 ± 1.2 18 ± 0.88 8.7 ± 3.3 17 ± 1.2 24 ± 2.4 14 ± 1.0 10 ± 3.2 
P4B2 
14 ± 2.2 17 ± 3.1 6.8 ± 0.9 0.23 ± 0.092 13 ± 1.5 10 ± 2.7 10 ± 1.7 5.2 ± 1.2 10 ± 0.83 10 ± 3.0 7.5 ± 0.88 6.1 ± 1.3 
P4B1 
>50 >50 27 ± 6.2 2.4 ± 1.2 >50 39 ± 1.0 15 ± 3.5 15 ± 3.7 >50 51 ± 4.0 46 ± 4.0 32 ± 8.1 
cisplatin 
11.3 ± 1.9 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 7.5 ± 1.3 nd nd 
oxaliplatin 
0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3.0 ± 1.2 0.9 ± 0.2 nd nd 
carboplatin 




3.2 ESI-MS Binding Studies 
3.2.1 Materials 
Q1 of sequence d(TGAG3TG3TAG3TG3TA2) (6991.25 g mol
-1, ε260 =  228700 M
-1 cm-1, PDB ID: 
1XAV) was purchased from IDT, Denmark. Porapak Rxn CX 20 cc column was purchased from 
Waters. Ammonium acetate was purchased from APS. Acetic acid was purchased from Chem-
supply. Previously synthesised asymmetric platinum-based complexes were utilised in this study.   
3.2.2 Preparation of Q1 
Q1 was purified using a Waters Porapak Rxn CX 20 cc column, where the flow rate was set to 1 
mL min-1 by a Bio-Rad Model EP-1 Econo Pump. The column was activated by eluting methanol 
(10 mL), water (10 mL) and finally ammonium acetate solution (100 mL, 150 mM). Q1 was then 
dissolved in ammonium acetate solution (500 μL, 150 mM) and loaded onto the column. Q1 was 
eluted with ammonium acetate solution (150 mM) and detection of Q1 was provided by a Bio-Rad 
Model EM-1 Econo UV Monitor at 254 nm. The eluted DNA was then lyophilised. The lyophilised 
DNA was dissolved in 320 μL of ammonium acetate buffer (150 mM, pH 7.0) and the 
concentration was determined using UV absorbance at 260 nm. ε260 was determined through the 
nearest neighbour model through IDT Biophysics tools with the Cavaluzzi-Borer correlation 
applied. Q1 (0.202 mM) was then annealed by heating in a water bath at 95 oC for 5 minutes and 
left to cool to room temperature.  
3.2.3 Preparation of ESI-MS samples 
A stock solution of each metal complex (2 mM) was prepared by dissolving in ammonium acetate 
buffer (150 mM, pH 7.0). Each sample was prepared with a Q1 concentration of 20 μM and the 
final volume of 30 μL was made up using ammonium acetate buffer (150 mM, pH 7.0). The 
amount of metal complex (MC) varied with each sample. In this study, the MC:Q1 ratios used 
were: 1:1, 3:1 and 5:1 (Table 3-2). Each sample was prepared directly before analysis, vortexed 







Table 3-2: Volumes of Q1, MC stock and buffer used to make ESI-MS samples.  
MC:Q1 1:1 3:1 5:1 
DNA (μL) 3 3 3 
MC (μL) 0.3 0.9 1.5 
Buffer (μL) 26.7 26.1 25.5 
Total (μL) 30 30 30 
 
3.2.4 Instrumentation 
Each sample was analysed using a Waters SYNAPT G2-S quadruple time-of-flight (Q-TOF) 
HDMS with a Z-spray ionisation source in ESI negative mode in a 700-3000 m/z threshold range. 
Spectra were obtained using a cone voltage of 50 V, a microchannel plate potential of 2.2 kV and 
a capillary tip potential of 2.2 kV. The desolvation gas flow rate was set to 150 L hr-1 at 150 oC 
with an ionisation source temperature of 70 oC.  Samples were injected using a KD Scientific 
Model 100 syringe pump at a rate of 5 μL min-1.  
3.2.5 Results and Discussion 
Figure 3-1 shows the negative ion ESI mass spectrum of free Q1 prior to the addition of any metal 
complex. Three charge states can be observed corresponding to [Q1 + 2NH4
+ - 8H+]6-, [Q1 + 2NH4
+ 
- 7H+]5- and [Q1 + 2NH4
+ - 6H+]4-. Of these three charge states, the 5- charge state is most abundant. 
No breakdown products can be observed in Figure 3-1, hence the reason why Q1 was chosen for 
these experiments, as this specific DNA is stable enough to be observed in abundance under 
experimental conditions. Ammonium acetate buffer was chosen for these experiments to maintain 





Figure 3-1. Negative ion ESI mass spectrum of the free Q1, showing the 6-, 5- and 4- charge 
states.  
 
Figure 3-2 shows the negative ESI mass spectrum for complex P4P1 ([Pt(3,4,7,8,-tetramethyl-
1,10-phenanthroline)(1,10-phenanthroline)]Cl2) interacting with Q1. In the ratio of 1:1, complex 
P4P1 binds to a total of 81% of all detected Q1, being both singly bound and doubly bound. With 
ratios of 3:1 and 5:1, complex P4P1 is bound to 100% of detected Q1 and no unbound Q1 can be 
observed in the spectra. Once fully bound, the main peaks that can be observed are the [Q1 + 
2MC2+ + 2NH4
+ - 11H+]5- and [Q1 + 2MC2+ + 2NH4
+ - 10H+]4-, with small amounts of [Q1 + 
2MC2+ + 2NH4
+ - 12H+]6-. At ratios 3:1 and 5:1, only doubly bound Q1 can be observed with no 





Figure 3-2. Negative ion ESI mass spectrum of Q1 with complex P4P1. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Figure 3-3 shows the negative ion ESI mass spectrum of Q1 with varying ratios of complex P4P2 
([Pt(3,4,7,8,-tetramethyl-1,10-phenanthroline)(4,7-dimethyl-1,10-phenanthroline)]Cl2). Complex 
P4P2 has a greater binding affinity towards Q1 when compared to complex P4P1, being 91% 
bound when in 1:1 ratio with Q1 (the highest of any complex). In the 3:1 and 5:1 spectra, P4P2 
was fully and doubly bound, with the main observable peaks being [Q1 + 2MC2+ + 2NH4
+ - 11H+]5- 
and [Q1 + 2MC2+ + 2NH4
+ - 10H+]4-, with small amounts of [Q1 + 2MC2+ + 2NH4
+ - 12H+]6-. In 
the 1:1 spectrum, both doubly bound and singly bound peaks were observed, however in the 3:1 





Figure 3-3. Negative ion ESI mass spectrum of Q1 with complex P4P2. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
The negative ESI mass spectrum for complex P4P3 ([Pt(3,4,7,8,-tetramethyl-1,10-
phenanthroline)(5,6-dimethyl-1,10-phenanthroline)]Cl2) is shown in Figure 3-4. In the 1:1 ratio, 
P4P3 is only 65% bound to Q1, which is significantly lower than the other 1,10-phenanthroline 
based complexes (P4P1, P3P1 and P4P2). Even though fully bound at the 3:1 ratio, two singly 
bound peaks ([Q1 + MC2+ + 2NH4
+ - 9H+]5- and [Q1 + MC2+ + 2NH4
+ - 8H+]4-) can be observed 
for complex P4P3, while at this ratio complexes P4P1, P3P1 and P4P2 were completely doubly 





Figure 3-4. Negative ion ESI mass spectrum of Q1 with complex P4P3. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Figure 3-5 shows the negative ESI mass spectrum of complex P3P1 interacting with Q1. With a 
MC:Q1 ratio of 1:1, P3P1 is 77% bound to Q1, which is only higher than for complexes 1,10-
phenanthroline-based complexes P4P3 and P4P6. As with most other 1,10-phenantrholine-based 
complexes, it is completely doubly bound at the ratios of 3:1 and 5:1, with the observed peaks 
being [Q1 + 2MC2+ + 2NH4
+ - 11H+]5- and [Q1 + 2MC2+ + 2NH4





Figure 3-5. Negative ion ESI mass spectrum of Q1 with complex P3P1. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Figure 3-6 shows the negative ESI mass spectrum of complex P4P6 interacting with Q1. When 
compared to other 1,10-phenanthroline-based complexes (P4P1, P4P2 and P4P3), P4P6 is only 
57% bound in the 1:1 ratio, which is a significantly lower. Additionally, in the 3:1 spectrum for 
complex P4P6, it can be observed that there are two singly bound peaks ([Q1 + MC2+ + 2NH4
+ - 
9H+]5- and [Q1 + MC2+ + 2NH4
+ - 8H+]4-) , which was not the case for other 1,10-phenantrholine 
based complexes which were all doubly bound at this ratio. In the 5:1 spectrum, complex P4P6 is 





Figure 3-6. Negative ion ESI mass spectrum of Q1 with complex P4P6. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Figure 3-7 displays the negative ESI mass spectrum of complex P4B1 ([Pt(3,4,7,8-tetramethyl-
1,10-phenanthroline)(2,2′-bipyridine)]Cl2) interacting with Q1. In the ratio of 1:1, P4B1 is 65% 
bound to Q1 which is lower than most bis-1,10-phenanthroline-based complexes, which could be 
explained by the fact that P4B1 has lower aromaticity. Even though completely bound in the 3:1 
and 5:1 ratios, small amounts of complex P4B1 (13%) remain singly bound in the 3:1 ratio. In 
contrast, P4B1 is almost completely doubly bound in the 5:1 ratio. In the 3:1 and 5:1 ratio two 
main doubly bound peaks can be observed ([Q1 + 2MC2+ + 2NH4
+ - 11H+]5- and [Q1 + 2MC2+ + 
2NH4





Figure 3-7. Negative ion ESI mass spectrum of Q1 with complex P4B1. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Figure 3-8 displays the negative ESI mass spectrum of complex P4B2 interacting with Q1. A few 
unidentified peaks can be observed in the 1:1 spectrum, occurring at 1552.2802, 1674.7068 and 
2093.3843 m/z. These additional peaks (1674.7068 and 2093.3843 m/z) appear again in the 5:1 
spectrum. These peaks may be due to other previously tested platinum(II) complexes binding with 
Q1 and are yet to be identified. At the ratio 1:1, the complex P4B2 is 81% bound to Q1. At the 3:1 
and 5:1 ratios, P4B2 is fully bound to Q1, however at the 3:1 ratio there is small amounts (6%) of 
singly bound Q1. Once fully bound, two main peaks ([Q1 + 2MC2+ + 2NH4
+ - 11H+]5- and [Q1 + 
2MC2+ + 2NH4





Figure 3-8. Negative ion ESI mass spectrum of Q1 with complex P4B2. MC:Q1 ratios: 5:1, 3:1 
and 1:1.  
 
Overall, this ESI-MS binding study confirmed that all synthesised complexes exhibited the ability 
to bind to G4-DNA with varying binding affinities. It was found that complex P4P2 exhibited the 
best binding affinity towards Q1, being almost completely bound (91% bound) at the 1:1 ratio and 
completely doubly bound at the 3:1 and 5:1 ratios. P4P2 structurally most closely resembles 
[Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)2]
2+, a G4-DNA stabiliser reported to have good 
binding affinity.115 This may indicate that the methyl groups in the 4 and 7 positions may be 
structurally important for G4-DNA binding. Figure 3-9 shows the percentage bound of each metal 
complex (in the 1:1 ratio) and their respective rankings based on percentage bound in the 1:1 ratio. 
After complex P4P2, the best Q1 binders are P4B2, followed by P4P1 and P3P1. These results 
are not in agreement with previously reported QSAR literature which correlates an increased 
aromatic surface area with an increased G4-DNA binding ability.
121 Contrary to the QSAR 
literature, the complex with the largest aromatic surface area (complex P4P6) ranked last in this 




the loss of an NH4
+ cation, indicating that intercalation/insertion was not the mode of binding for 
the synthesised complexes. This indicates that stacking or groove binding interactions may be the 
predominant binding modes for these complexes. In the spectra for complex P4B2, significantly 
large unidentified peaks can be observed when compared to other complexes, where only smaller 
insignificant extra peaks can be observed. Future experiments are required in order to observe if 
these unidentifiable peaks persist. However, due to time restraints, binding experiments for P4B2 
were not repeated and these peaks are yet to be identified.  
 
Figure 3-9. Percentage bound (in the 1:1 ratio) and rankings for each metal complex based on 








3.3 CD Melting Studies 
3.3.1 Materials 
Q1 of sequence d(TGAG3TG3TAG3TG3TA2) (6991.25 g mol
-1, ε260 = 228700 M
-1 cm-1, PDB ID: 
1XAV) and Q2 of sequence 5′-GGG GTT TTG GG-3′ (6952.51 g mol-1, ε260 = 105100 M
-1 cm-1, 
PDB ID: 1LVS) were purchased from IDT, Denmark. Potassium dihydrogen phosphate (KH2PO4) 
and dipotassium phosphate (K2HPO4) were purchased from Ajax Chemicals and The British Drug 
Houses, respectively. Potassium fluoride (KF) was purchased from Sigma-Aldrich.   
3.3.2 Preparation of G4-DNA 
Preparation of Q1 
Q1 was prepared in potassium phosphate buffer consisting of KH2PO4/K2HPO4 (25 mM, pH 7.0) 
and KF (50 mM). Q1 was dissolved in the required amount of potassium phosphate buffer in order 
to make a 0.2 mM Q1 solution, based on the amount of DNA provided by the supplier. Q1 was 
then annealed by heating to 95 oC for 5 minutes and allowed to cool to room temperature, forming 
the 1XAV G4-DNA motif. In order to confirm that the correct DNA structure was formed, a SRCD 
spectrum (Figure 3-10) of 1XAV G4-DNA was performed at the AU-CD beam line facility at the 
ASTRID2 storage ring facility, Aarhus University, Denmark. The spectrum was obtained at 25 oC, 
between 170-330 nm. The spectrum was obtained using 1 nm steps, a 2.1 second dwell time and 
5 accumulations.  Afterwards, the concentration of Q1 was determined spectrophotometrically 
using absorbance at 260 nm using the AU-CD beam line, based on ε260 = 228700 M
-1 cm-1, 
calculated by the nearest neighbour method.  
 



















Preparation of Q2 
Q2 was prepared in potassium phosphate buffer consisting of KH2PO4/K2HPO4 (25 mM, pH 7.3) 
and KF (75 mM). Q2 was dissolved in the required amount of potassium phosphate buffer in order 
to make a 0.1 mM Q2 solution, based on the amount of DNA provided by the supplier. Q2 was 
then annealed by heating to 95 oC for 10 minutes and allowed to cool to room temperature, forming 
the 1LVS G4-DNA motif. In order to confirm that the correct DNA structure was formed, a CD 
spectrum (Figure 3-11) of 1LVS G4-DNA was performed using a Jasco model J-810 CD 
polarimeter. The spectrum was obtained at 20 oC, between 200-350 nm. The spectrum was 
obtained with a 100 nm min-1 scan rate, a 1 second response time and 20 accumulations. 
Afterwards, the concentration of Q2 was determined spectrophotometrically using absorbance at 
260 nm, based on ε260 = 105100 M
-1 cm-1, calculated by the nearest neighbour method.  
 
Figure 3-11. Smoothed CD spectrum of Q2 after annealing.  
 
3.3.3 CD Melt Methodology 
Melting Methodology with Q1 with/without P4P1 and P4P2  
The stabilising effect of P4P1 and P4P2 towards Q1 was determined. All SRCD experiments were 
performed at the AU-CD beam line at the ASTRID2 storage ring facility, Aarhus University, 
Denmark. All SRCD experiments were performed using a suprasil quartz cuvette, consisting of a 
0.01 mm path length.  Temperature was regulated by a Eurotherm temperature regulator. The AU-



















mm (horizontal), with a sample to detector distance of 25 mm. The AU-CD beamline also operates 
in top-up mode with a current of 120 mA. 2 mM metal complex stock solutions were prepared in 
water. Each experimental sample consisted of a Q1 concentration of 0.1 mM and 1 equivalent of 
each metal complex (i.e. P4P1 or P4P2) to be tested in KH2PO4/K2HPO4 (25 mM, pH 7.0) and 
KF (50 mM). The Q1 sample with no metal complex was prepared using the same Q1 
concentration and same buffer.  Samples were allowed to equilibrate for 15 minutes prior to 
measurements. Temperature scans began at 25 oC and increased in increments of 5 oC towards 85 
oC. The temperature slope was set to 1 oC min-1. For each temperature increment, an equilibration 
time of 5 minutes was allowed before a spectrum was obtained from 178-330 nm. Each scan 
consisted of a 1 nm increment and 5 accumulations. Experiments were performed in duplicate for 
each metal complex (i.e. P4P1 or P4P2).  
Melting Methodology with Q2 with/without All Metal Complexes 
The stabilising effect of each synthesised metal complex towards Q2 was determined. All CD 
experiments were performed using a Jasco model J-810 CD polarimeter equipped with a Jasco 
peltier temperature regulator and a 1 mm quartz cuvette. 2 mM metal complex solutions were 
prepared in water. Each experimental sample consisted of a Q2 concentration of 0.04 mM with 1 
equivalent of each metal complex to be tested in KH2PO4/K2HPO4 (25 mM, pH 7.3) and KF (75 
mM). The Q2 sample with no metal complex was prepared with the same Q2 concentration and 
same buffer. Samples were allowed to equilibrate for 15 minutes prior to measurements. In 
addition to confirming that Q2 had folded into the correct motif after annealing, a CD spectrum 
was obtained before and after each melting experiment to confirm if the same structure was 
retained after adding metal complex. The spectra were obtained at 20oC, between 200-350 nm. 
The spectra were obtained with a 100 nm min-1 scan rate, a 1 second response time and 4 
accumulations.  Each melt was obtained at 287 nm in the range of 20-100 oC, with a temperature 
slope of 2 oC min-1. The data pitch and response time was set to 1 oC and 4 seconds respectively.  
3.3.4 Determination of TM (Melting temperature) 
TM Determination of Q1 with/without P4P1 and P4P2 
TM of Q1 with/without P4P1 and P4P2 was determined by finding the first and second derivative 




TM Determination of Q2 
The Q2 melting chromatogram was smoothed using the Savitzky-Golay method with 20 points of 
window. Afterwards the data was normalised (0,1) to generate a sigmoidal CD melting 
chromatogram displaying the fraction of DNA folded. To obtain TM, the data was fitted with a 
Boltzmann sigmoidal function (Equation 3.1) using Origin 8.5: 
𝐶𝐷 = 𝑏 +  
(𝑎 − 𝑏)





where 𝑎 and 𝑏 are the highest and lowest signals, respectively and 𝑇𝑀 is the point of inflexion.  
TM Determination of Q2 with Each Metal Complex 
TM of Q2 with each metal complex was determined by finding the first and second derivative of 
the raw CD melting curves, where the point of inflexion was assigned as TM.  The first and second 
derivatives were smoothed using 15 and 25 points of window, respectively.  
3.3.5 Results and Discussion 
The melt of Q2 is shown in Figure 3-12 and was able to be fitted with a Boltzmann sigmoidal 
function in order to determine TM from the point of inflexion. As for the melts of Q2 with the 
synthesised metal complexes, the CD melting curves could not be fitted with a Boltzmann 
sigmoidal function. Therefore, TM values were determined by taking the first and second 
derivatives of the CD curves, where the point of inflexion gives TM. Figure 3-13 outlines the 
process of determining TM for complex P4P6. The melting of Q2 with no metal complex indicated 
a monophasic melting profile, as confirmed by first and second derivative of its melting curve 
(Appendix E-8). On the contrary, the melting profiles of Q2 with metal complexes were mostly 
biphasic, and therefore two TM values were obtained, where the first and second TM values are 
referred to as TA and TB in Table 3-3. P4P3 was an exception, where three points of inflexions 
were found, reported as TA, TB and TC. P4P2 exhibited a monophasic melt with Q2 and only TA is 






Figure 3-12. Normalised and smoothed Boltzmann plot showing the CD melting profile of Q2.  
 
Figure 3-13. First (top) and second (bottom) derivative of the CD intensity of complex P4P6 


































Biphasic melting was most apparent with complex P4P1 as it could be seen in its melting curve 
(Figure 3-14). In order to investigate this trend further, CD spectra were obtained at different 
temperatures with Q2 and 1 equivalent of P4P1, under the same conditions as with melting 
experiments (Figure 3-15). Q2 is a hybrid structure at room temperature, consisting of parallel and 
antiparallel strands. As seen in Figure 3-15, the presence of P4P1 with Q2 induces a structural 
change in Q2 at room temperature, favouring the antiparallel quadruplex over the parallel 
quadruplex. This structural change due to P4P1 can be deduced by a reduction in the minimum 
and peak at 240 and 260 nm respectively, which is indicative of a parallel complex.122 In contrast, 
the peak intensity at 290 nm increases in the presence of P4P1, which indicates an antiparallel 
structure.122 After the addition of P4P1 to Q2, the same sample was heated to 70 oC and the 
spectrum obtained indicated that the ratio between parallel and antiparallel stands returned to the 
same level as the native Q2 structure at room temperature. The same sample was then heated to 85 
oC, in 5 oC intervals, while taking a spectrum at each interval. A transition state towards an 
antiparallel structure from a hybrid structure occurred, which can be observed from the 70-85 oC 








P4P2  92 - - 1 
P4P1  51 89 - 2 
P4P6  46 86 - 3 
P4P3 33 51 83 4 
P4B2  48 83 - 5 
P4B1   50 80 - 6 
P3P1  55 72 - 7 
1LVS G4-







Figure 3-14. Normalised and smoothed biphasic plot showing the melting profile of Q2 with 
P4P1.   
 







































Q2 (20 ⁰C) Q2 + P4P1 (20 ⁰C, before heating)
Q2 + P4P1 (70 ⁰C) Q2 + P4P1  (75 ⁰C)
Q2 + P4P1  (80 ⁰C) Q2 + P4P1 (85 ⁰C)




As with ESI-MS binding studies, complex P4P2 performed best in CD melting studies, producing 
TA of 92 
oC, the highest of any complex. P4P2 is structurally most similar to [Pt(Me4phen)2]
2+, a 
G4-DNA stabiliser reported to exhibit good binding affinity.
115 P4P2 was closely followed by 
complexes P4P6 and P4P1, producing a TB value of 83 
oC. This CD melting study did not follow 
the reported trend in the QSAR literature which states that a larger aromatic surface area 
corresponds to an increased G4-DNA affinity,
123 as other factors such as solubility, stability and 
planarity may influence DNA binding. Complex P4P6, even though consisting of the largest 
aromatic surface area, gave the third best result in this study, which may indicate that despite the 
largest surface area, this complex was not effectively stacking with Q2.  
The results for SRCD experiments are summarised in Table 3-4 and an example melt is shown in 
Figure 3-16. SRCD melting curves could not be fitted using a Boltzmann sigmoidal curve and 
therefore TM was determined using the first and second derivative method. An example of a 
melting curve for complex P4P1 and its melting point determination is shown in Figures 3-17 and 
3-18. SRCD TM values between duplicate experiments were variable (Table 3-4). According to 
Table 3-4, complex P4P1 produced two different melting temperatures. In the first experiment, 
complex P4P1 appeared to destabilise Q1, while in the second experiment P4P1 stabilised Q1. In 
comparison, complex P4P2 appeared to destabilise Q1, which is in contradiction to ESI-MS 
binding studies, where complex P4P2 showed the best binding affinity towards Q1. These 
experiments should be repeated in order to determine whether consistent results could be achieved.  
However, due to time restraints, these experiments could not be repeated on the SRCD instrument 





Figure 3-16. CD spectra of Q1 at various temperatures.  
 Table 3-4. Average TM values of Q1 with/without metal complexes.  
 
 
Figure 3-17. Melting curve for complex P4P1 (second duplicate). Wavelengths: 185 nm (blue), 
208 nm (red), 244 nm (green) and 265 nm (purple).  
Compound First Duplicate TM (oC) Second Duplicate TM (oC) 
P4P1 48.59 56.72 
P4P2 47.44 48.60 





Figure 3-18. First and second derivative of the CD intensity of complex P4P1 (second 
duplicate). Points of inflexion are marked with crosses and reported as TM.  
 
Q2 was chosen for CD experiments due to its relative low TM when compared to other G4-DNA 
substrates. The use of Q1 (used in SRCD experiments) was explored as a potential G4-DNA 
substrate for CD experiments. However, the SRCD melting experiment with Q1 could not be 
reproduced with the Jasco model J-810 CD polarimeter, where a higher TM was observed. The 
AU-CD beam line SRCD facility is equipped with a nitrogen gas plumbing system, allowing for 
long experiments (~ 8 hours) to be performed. In comparison, the Jasco model J-810 CD 
polarimeter obtains its nitrogen gas from cylinders, making longer experiments impractical. It was 
initially hypothesised that the destabilisation of Q1 may be time-dependent, which would explain 
the difference in stability observed from the AU-CD beam line and the Jasco CD polarimeter. This 
hypothesis was tested by conducting a melt of Q1 at 265 nm using the Jasco CD polarimeter and 
the same buffer as SRCD experiments, where the temperature slope was changed to 10 oC hr-1, 




in the TM value for Q1 (Figure 3-19), suggesting a different cause. A larger cuvette was used for 
CD melting experiments. It is hypothesised that the smaller cuvette used in SRCD experiments 
allowed for more efficient heat transfer and which may contribute to the lower observed TM value. 
However, since the smaller cuvette size was unavailable for use in CD experiments, this hypothesis 
could not be tested.  
 
Figure 3-19. Normalised and smoothed Boltzmann plot showing the CD melting profile of Q1 







      












































4.1 Computer System – Hardware and Software 
All simulations were conducted on an Intel Core i5-6500 CPU with 8 GB DDR3 RAM running on 
a x64-bit operating system. Avogadro (1.2.0), MGLTools (1.5.6), UCSF Chimera (1.13.1), and 
Chem Draw (12.0) were utilised in preparing the ligands and substrates for docking analysis. 
Autodock Vina (1.1.2) was utilised for the docking simulation.112 Statistical analysis of results was 
done on Microsoft Excel 2013 in order to generate box and whisker plots.  
4.2 Methodology 
Each metal complex (ligand) was first prepared by drawing the structure of each complex in Chem 
Draw. Each metal complex was then imported into Avogadro as a CDXML file. In Avogadro each 
model was refined and optimised using the UFF force field function using the steepest decent 
gradient method, ensuring that each metal complex was square planar and that each metal complex 
was computationally in the most stable conformation. Using AutoDock Tools, each ligand was 
checked for rotational bonds and torsions, ensuring all bonds were the correct type. Afterwards, 
each complex model was converted to a PDBQT input file. Each G4-DNA and dsDNA substrate 
model was obtained from the Protein Data Bank as a PDB file. Additional residues such as water, 
bound ligands and cations were removed from the substrate using USCF Chimera. Using 
AutoDock Tools, polar hydrogens were added to each substrate and a search space gridbox was 
established. The docking region utilises a gridbox which covers the entire substrate structure. Each 
gridbox was optimised for minimum volume in order to accelerate calculation time. Each substrate 
was then saved as a PDBQT file ready for docking analysis.  
Each docking experiment was repeated five times with an exhaustiveness value of 48 and an 
energy range value of 4. After each docking simulation, Autodock Vina generated an output file 
with the top nine calculated minimum binding affinities (kcal mol-1) and the root mean square 
deviation (RMSD) for each pose, which denotes the difference between the predicted top 
conformation and each of the following poses. To view each docking conformation, UCSF 




4.3 Choice of DNA Substrates 
4.3.1 Human c-myc Oncogene Promoter Quadruplex (PDB: 1XAV)74 
1XAV G4-DNA (Figure 4-1) is a solution quadruplex structure found in the human c-myc promoter 
region, a 22mer consisting of the sequence [d(TG(AGGGTGGGT)2AA]. This quadruplex is a 
monomolecular parallel quadruplex with propeller loops.124 Overexpression of c-myc plays a vital 
role in in cancer metabolism and is necessary for supporting the cancer cells increased need for 
nucleic acids, proteins, lipids and rapid cellular division.83 The fact that the c-myc is dysregulated 
or overexpressed in approximately 70% of cancer cells makes it a suitable target for cancer 
therapy.125 
4.3.2 Human Telomeric Parallel Quadruplex (PDB: 1KF1)126 
1KF1 G4-DNA (Figure 4-1) is a well-known crystal structure of a quadruplex found within the 
human telomere, a 22mer consisting of the sequence [d(AGGG(TTAGGG)3)]. 1KF1 G4-DNA is 
a full parallel quadruplex with three reversal loops located on the outside of the core and has a 
propeller arangement.127 This structure also has an approximate four-fold symmetry and is 
stabilised by K+ ions.  
4.3.3 Dimeric Fold-back Quadruplex (PDB: 1LVS)128 
1LVS G4-DNA (Figure 4-1) is the solution structure of a bimolecular quadruplex structure, a 
11mer consisting of sequence [d(G4T4G3)]2. This sequence forms an asymmetric dimer fold-back 
structure consisting of three stacked G-quartets. The inner G-Quartets show planarity, while the 
two outer most G-Quartets exhibit out-of-plane tilting. It has previously been shown that 
deviations from planarity would lead to ideal stacking with the nitrogenous bases within thymidine 
loops.  
4.3.4 Classical B-DNA (PDB: 1BNA)129 
1BNA dsDNA (Figure 4-1) is the crystal structure of a synthetic dsDNA, a 12mer of sequence 
[d(CGCGAATTCGCG)2]. The right-handed double-stranded B helix arranges into slightly more 
than one complete turn.  Two ends of the helix overlay each other and interlock minor grooves 
with nearby molecules. This structure is commonly used as a substrate in DNA docking studies in 




4.3.5 Bisintercalated dsDNA (PDB: 1CX3)130 
1CX3 dsDNA (Figure 4-1) is the solution structure of a DNA duplex, a 6mer of sequence 
[d(ATGCAT)]2. The DNA structure consists of LU-79553 (a topoisomerase II inhibitor) 
bisintercalating with the DNA structure. The two naphthalimide chromophores of the drug were 
found to stack with G and A bases from opposite strands.   
 
Figure 4-1. Images of G4-DNA and dsDNA substrates as used in this docking study. Note: non-
standard residues such as water, bound ligands and cations have been removed. Images rendered 




4.4 Results and Discussion 
In this study, the synthesised metal complexes were docked with five DNA substrates, two of 
which were dsDNA, while three were G4-DNA.  Docking with dsDNA was performed in order to 
assess any selectivity of the synthesised complexes towards G4-DNA. All docking simulations for 
each metal complex towards each substrate was repeated five times, as recommended by the 
authors of the software, resulting in a total of 175 docking simulations. As it was unfeasible to 
display the results for all simulations, average binding affinities are displayed in Table 4-1. Also 
presented are box and whisker plots showing the spread of binding affinities for each metal 
complex with their respective substrate (Figures 4-2 to 4-6) as well as images of different binding 
poses (Appendix F).   
Table 4-1. Mean binding affinities for each synthesised complex with each respective G4-DNA 
and dsDNA substrate.  
Complex 
G4-DNA Mean Binding Affinity (Kcal 
mol-1) 
dsDNA Mean Binding Affinity (Kcal 
mol-1) 
1XAV 1VLS 1KF1 1BNA 1CX3 
P4P1 -7.77 -7.25 -9.74 -8.45 -6.62 
P4P2 -7.82 -7.28 -10.26 -8.65 -6.90 
P4P3 -7.87 -7.68 -10.03 -8.78 -6.87 
P4P6 -8.32 -8.40 -10.63 -9.28 -7.21 
P4B1 -7.46 -6.96 -9.00 -7.89 -6.46 
P4B2 -7.48 -7.20 -9.39 -8.19 -6.87 






Figure 4-2. Box and whisker plot showing the binding affinities of the synthesised complexes 
towards 1XAV G4-DNA. 
 
Figure 4-3. Box and whisker plot showing the binding affinities of the synthesised complexes 





Figure 4-4. Box and whisker plot showing the binding affinities of the synthesised complexes 
towards 1LVS G4-DNA. 
 
Figure 4-5. Box and whisker plot showing the binding affinities of the synthesised complexes 






Figure 4-6. Box and whisker plot showing the binding affinities of the synthesised complexes 
towards 1CX3 dsDNA. 
 
From the results displayed in the above Table 4-1 and Figures (4-2 to 4-6), it can be shown that 
complex P4P6 has the best binding affinity towards all DNA substrates, which is expected as this 
complex has the largest aromatic surface area. A similar trend can be observed for complexes 
consisting of two coordinated 1,10-phenanthroline-based ligands (P4P1, P4P2, P4P3 and P3P1), 
where these complexes exhibited better binding affinities than complexes containing 2,2'-
bipyridine-based ligands (P4B1 and P4B2). This is in agreement to previously published literature 
which links an increased aromatic surface area with a greater ability to stack with G4-DNA.
123 
Additionally, complexes containing 2,2'-bipyridine-based ligands are less planar relative to 
complexes consisting of only 1,10-phenantrholine-based ligands, suggesting that increased 
planarity may also contribute to G4-DNA binding.   
When compared to 1BNA dsDNA, all complexes showed selectivity towards only telomeric G4-
DNA (1KF1), however no selectivity was exhibited towards 1LVS and 1XAV G4-DNA DNA. All 
complexes were selective towards all G4-DNA substrates when compared to 1CX3 dsDNA. All 
complexes were bound to 1KF1 G4-DNA via end-stacking and to 1LVS G4-DNA via groove 




binding was also observed, in particular complexes P3P1 and P4P6. Complex P4B2 have also 
shown to bind to 1CX3 via intercalation (Appendix F-6).  
Complex [Pt(Me4phen)2]
2+ was previously shown to be a strong G4-DNA binder.
115 Complexes 
P4P1, P4P2 and P4P3 have the same aromaticity as complex P3P1. However, the complexes 
consisting of the Me4phen ligand generally performed much better across G4-DNA models and 
performed similarly with dsDNA. This data suggests that the Me4phen is an important ligand for 
G4-DNA binding.  
In summary, this study serves as a useful screening process to determine potential G4-DNA 
binding, selectivity and binding modes of each platinum(II) complex. Complex P4P6 was found 
to show the best binding affinity across all G4-DNA models. The results of this study is in 
agreement with the QSAR literature which states that greater aromaticity leads to improved G4-
DNA binding via stacking. This study did not correlate with in vitro studies (Chapter 3), as other 
factors such as solubility may affect the extent of binding. Contrary to the docking simulations, 
P4P6 was ranked last in ESI-MS binding studies and third in CD binding studies. The main 
limitation of this study is that it investigates a static substrate, where only the metal complex ligand 
is considered flexible. This study was chosen as it decreases the computational requirements and 













Table 4-2. set. Rankings of each metal complex towards each G4-DNA substrate. Green and 
red represent the highest and lowest ranked complexes, respectively. 
 
Table 4-3. set. Rankings of each metal complex towards each dsDNA substrate. Green and 























5.1 Synthesis and Characterisation of Platinum(II) Complexes 
In this project, a total of seven novel platinum(II) complexes were synthesised and subsequently 
characterised using a variety of techniques, including NMR, UV-Vis, HR-MS as well as HPLC. 
The synthetic method for synthesising these types of platinum(II) complexes underwent major 
developments.  
The synthetic method for the coordination of the first polyaromatic ligand (i.e. Me4phen) was 
found to occur best via a slow crystallisation of the desired [Pt(Me4phen)Cl2] in a mixture of water 
and DMSO. The use of a microwave reactor significantly decreased the yield from 83% to 56%. 
The most apparent reason for the decreased yield when using the microwave reactor is that the 
product was not allowed to crystallise slowly over time, resulting in a very fine solid that was 
difficult to collect by vacuum filtration.  
In terms of coordinating the second polyaromatic ligand, initially the reactions were performed by 
refluxing the [Pt(Me4phen)Cl2] precursor and the desired polyaromatic ligand in ethylene glycol 
and water, which was very time consuming due to poor solubility of reagents. The use of a 
microwave reactor not only decreased reaction time, increased yield and improved solubility, but 
also allowed the product to be isolated as a water soluble chloride salt, allowing for purification 
by flash chromatography using a water to methanol gradient. 
Future research should focus on further synthetic method development in order to increase yields 
and purity of the crude product. The reaction conditions described previously resulted in the 
formation of the desired product in addition to two undesired by-products ([Pt(1,0-
pheanantrholine)2]
2+ and [Pt(2,2'-bipyridine)2]
2+ based compounds). Further testing would involve 
optimising reaction conditions such as temperature and solvent systems in order to minimise 
unwanted by-product formation and maximise the formation of the desired compound. Additional 
purification developments could focus on improved flash chromatography solvent gradients with 
better separation, especially for compounds such as P4P6 which required further purification after 
undergoing flash chromatography. Also, future research could attempt to utilise ligands such as 
1,10-phenantrholine-5-carboxylic acid which can be linked with linkers such as spermine in order 
to facilitate the synthesis of dinuclear platinum(II)-based G4-DNA stabilisers which could bind to 







Figure 5-1. A dinuclear complex interacting with 1KF1 G4-DNA via end-stacking. Image 
rendered using UCSF Chimera.  
 
5.2 Cytotoxicity Studies 
All compounds were found to exhibit anticancer activity, with 1,10-phenanthroline-based 
complexes P3P1, P4P1 and P4P3 exhibiting the best activity. Complex P3P1 did not perform well 
when assessed using docking simulations, CD melts and ESI-MS binding studies, however it 
ranked first in cytotoxicity against cancer cell lines. This data suggests that the good cytotoxicity 
of P3P1 is due to a different mechanism of action and not due to G4-DNA binding. Future tests 
could include testing the synthesised complexes on various non-cancer cell lines in order to assess 
any selectivity towards cancer cell lines.  
5.3 ESI-MS Binding Studies 
Each synthesised platinum(II) complex showed the ability to bind to 1XAV G4-DNA. This study 
did not support previously published QSAR literature which states that an increased aromaticity 
leads to improved G4-DNA binding. Complex P4P6 which has the largest aromatic surface area, 
was ranked last in this ESI-MS binding study. Complex P4P2, which is structurally most similar 
to the previously reported potent G4-DNA stabiliser (Pt(Me4phen)2]
2+), showed the best binding 
affinity towards 1XAV G4-DNA. Future research should focus on determining the potential 
selectivity of the synthesised complexes towards G4-DNA over dsDNA. There are various dsDNA 




5.4 CD Melting Studies 
Overall, each complex showed the ability to stabilise 1LVS G4-DNA. The results of this study are 
partially in agreement with ESI-MS, with complex P4P2 being the best G4-DNA stabiliser. Future 
experiments may include testing all synthesised complexes using synchrotron radiation circular 
dichroism (SRCD) spectroscopy, which consists of a high intensity light source and is able to 
detect peaks that are not able to be detected using a Jasco model J-810 CD polarimeter (i.e. < 200 
nm). Also the higher intensity light source may result in higher quality spectra with less noise. 
Additionally, the underlying cause of the difference in stability (under identical buffer conditions) 
of 1XAV G4-DNA between the Jasco model J-810 CD polarimeter and the AU-CD beamline 
should be investigated. It is hypothesised that the difference between the cuvette sizes used 
between the two spectrometers may be a contributing factor for the difference in observed TM, 
since a smaller cuvette would allow for more efficient heat transfer and may have been responsible 
for the lower observed TM value.  
5.5 In Silico Molecular Docking Simulations 
Each synthesised platinum(II) complex underwent docking simulations against five substrates, 
three being G4-DNA and two being dsDNA. From this study, the DNA binding affinity and 
potential binding modes were determined. The results obtained from this docking study are in 
agreement with previously published QSAR literature which states that a larger aromatic surface 
area results in better G4-DNA affinity. Therefore, complex P4P6 consisting of the Dpq ligand 
ranked first in this study. Complexes consisting of two 1,10-phenanthroline-based ligands also 
showed better binding than complexes consisting of one 2,2'-bipyridine-based ligand. In contrast, 
the results of this docking study were not in agreement with CD and ESI-MS binding studies 
(Section 3).  
Future research may include docking simulations on a larger library of potential platinum(II)-based 
G-quadruplex stabilisers consisting of various types of 1,10-phenanthroline-based ligands. 
Dinuclear platinum(II) may allow for improved binding and should also be included in these 
docking simulations. Further, molecular dynamics can allow for quantification of electrostatic 
interactions in solvated systems so that in vivo systems can be more accurately modelled in 




5.6 Final Rankings of Compounds 
The final rankings of the synthesised complexes is summarised in Table 5-1, ranked from highest 
(1) to lowest (7). Ranks were assigned based on the average binding affinity (docking), TM (CD 
melts), percentage bound (ESI-MS binding) and IC50 values (cytotoxicity assay) for each complex. 
Complex P4P2 exhibited the best overall rank and performed the best in in vitro G4-DNA binding 
studies, while complex P3P1 exhibited the best cytotoxicity against cancer cells. Docking 
simulations did not correlate well with CD and ESI-MS binding studies, therefore docking studies 
may not always translate into in vitro studies.  
Table 5-1. Final rankings of synthesised complexes. Green and red colours represent highest and 
lowest ranked complexes for each test, respectively.  
Complex Docking CD Melt ESI-MS IC50 Overall 
P4P1 4 2 3 2 2 
P4P2 3 1 1 4 1 
P4P3 2 4 6 3 3 
P4P6 1 3 7 6 = 4 
P4B1 7 6 5 7 6 
P4B2 6 5 2 5 5 
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Appendix A: Nuclear Magnetic Resonance Spectroscopy 
 
Appendix A-1. 1H NMR spectrum of complex P4P1 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 16.   
 
Appendix A-2. COSY NMR spectrum of complex P4P1 obtained on a Bruker 400 MHz 






Appendix A-3. 195Pt-HMQC NMR spectrum of complex P4P1 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 8.   
 
 
Appendix A-4. 1H NMR spectrum of complex P4P1 obtained on a Bruker 400 MHz 





Appendix A-5. COSY NMR spectrum of complex P4P2 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 2.   
 
Appendix A-6. 195Pt-HMQC NMR spectrum of complex P4P2. obtained on a Bruker 400 MHz 






Appendix A-7. NOESY NMR spectrum of complex P4P2. obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 32.   
 
Appendix A-8. 1H NMR spectrum of complex P4P6 obtained on a Bruker 400 MHz 






Appendix A-9. COSY NMR spectrum of complex P4P6 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 16.   
 
Appendix A-10. 195Pt-HMQC NMR spectrum of complex P4P6 obtained on a Bruker 400 MHz 





Appendix A-11. 1H NMR spectrum of complex P4B1 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 16.   
 
 
Appendix A-12. COSY NMR spectrum of complex P4B1 obtained on a Bruker 400 MHz 





Appendix A-13. 195Pt-HMQC NMR spectrum of complex P4B1 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 1344.   
 
 
Appendix A-14. 1H NMR spectrum of complex P4B2 obtained on a Bruker 400 MHz 





Appendix A-15. COSY NMR spectrum of complex P4B2 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 2.   
 
 
Appendix A-16. 195Pt-HMQC NMR spectrum of complex P4B2 obtained on a Bruker 400 MHz 






Appendix A-17. 1H NMR spectrum of complex P3P1 obtained on a Bruker 400 MHz 
spectrometer. Solvent: D2O, Number of accumulations: 16.   
 
Appendix A-18. COSY NMR spectrum of complex P3P1 obtained on a Bruker 400 MHz 






Appendix A-19. 195Pt-HMQC NMR spectrum of complex P4B2 obtained on a Bruker 400 MHz 
















Appendix B: Mass Spectroscopy Characterisation Data 
 
Appendix B-1. Mass spectrum of complex P4P1. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 
Desolvation gas flowrate: 150 L hr-1.  
 
Appendix B-2. Mass spectrum of complex P4P3. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 





Appendix B-3. Mass spectrum of complex P4P6. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 
Desolvation gas flowrate: 150 L hr-1.  
 
 
Appendix B-4. Mass spectrum of complex P4B1. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 





Appendix B-5. Mass spectrum of complex P4B2. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 
Desolvation gas flowrate: 150 L hr-1.  
Appendix B-6. Mass spectrum of complex P3P1. Solvent: ammonium acetate buffer (H2O, 150 
mM, pH 7), Lockmass: leucine encephalin, Cone voltage: 50 V, Temperature: 150 oC, 





Appendix C: High Pressure Liquid Chromatography 
 
Appendix C-1. HPLC Chromatogram of complex P4P1. Top: 214 nm, bottom: 254 nm.  
 






Appendix C-3. HPLC Chromatogram of complex P4P3. Top: 214 nm, bottom: 254 nm.  
 





Appendix C-5. HPLC Chromatogram of complex P4B1. Top: 214 nm, bottom: 254 nm.  
 






















Appendix D: Ultra Violet-Visible Spectroscopy  
 
Appendix D-1. UV-Vis spectrum and extinction coefficient determination of complex P4P2.  
 





Appendix D-3. UV-Vis spectrum and extinction coefficient determination of complex P4P6. 
 





Appendix D-5. UV-Vis spectrum and extinction coefficient determination of complex P4B2. 
 




Appendix E: CD/SRCD Melting Studies 
 

































Q2 + P4P2 Q2 + P4P3 Q2 + P4B2 Q2 + P3P1






Appendix E-2. First (top) and second derivative (bottom) of the CD melting curve for complex 

























Appendix E-3. First (top) and second derivative (bottom) of the CD melting curve for complex 


























Appendix E-4. First (top) and second derivative (bottom) of the CD melting curve for complex 


























Appendix E-5. First (top) and second derivative (bottom) of the CD melting curve for complex 





























Appendix E-6. First (top) and second derivative (bottom) of the CD melting curve for complex 




























Appendix E-7. First (top) and second derivative (bottom) of the CD melting curve for complex 





















































Appendix E-9. SRCD melting curve of complex P4P1 (first duplicate) with Q1. Wavelengths: 
185 nm (blue), 208 nm (red), 244 nm (green) and 265 nm (purple).  
 
Appendix E-10. SRCD melting curve of complex P4P2 (first duplicate) with Q1. Wavelengths: 





Appendix E-11. SRCD melting curve of complex P4P2 (second duplicate) with Q1. 
Wavelengths: 185 nm (blue), 208 nm (red), 244 nm (green) and 265 nm (purple).  
Appendix E-12. SRCD melting curve of Q1. Wavelengths: 185 nm (blue), 208 nm (red), 244 nm 







Appendix E-13. First (top) and second derivative (bottom) of the SRCD melting curve for 
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Appendix E-14. First (top) and second derivative (bottom) of the SRCD melting curve for 
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Appendix E-15. First (top) and second derivative (bottom) of the SRCD melting curve for 
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Appendix E-16. SRCD spectrum of Q1 with P4P1 at various temperatures (first duplicate).  
 





Appendix E-18. SRCD spectrum of Q1 with P4P2 at various temperatures (first duplicate).  
 




Appendix F: Docking Simulations  
Appendix F-1. Binding poses of complex P3P1 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
 
Primary pose: end stacking 
 











Primary pose: groove binding 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 






Appendix F-2. Binding poses of complex P4P2 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
 

















Primary pose: groove binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 






Appendix F-3. Binding poses of complex P4P3 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
















Primary pose: groove binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 
 




Appendix F-4. Binding poses of complex P4B1 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
Primary pose: end stacking 
 











Primary pose: groove 
binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 
 






Appendix F-5. Binding poses of complex P4P6 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
Primary pose: groove binding 
 













Primary pose: groove binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 
 







Appendix F-6. Binding poses of complex P4B2 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
 
Primary pose: end-stacking 
 












Primary pose: groove binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 
 
Primary pose: intercalation 
 





Appendix F-7. Binding poses of complex P4P1 towards G4-DNA and dsDNA substrates.  
1XAV G4-DNA 1KF1 G4-DNA 1LVS G4-DNA 
 
 
Primary pose: end-stacking 
 







Primary pose: end stacking 
 
 
Primary pose: groove binding 
 
1BNA dsDNA 1CX3 dsDNA 
 
Primary pose: groove binding 
 
 







Appendix F-8. Grid-box parameters for each substrate. 
Substrate 
ID size_x size_y size_z center_x center_y center_z 
Volume 
(A3) 
1XAV 102 72 86 -0.304 1.308 0.844 631584 
1LVS 70 88 82 0.028 0.694 -1.056 505120 
1KF1 100 88 122 23.972 -0.389 -8.889 1073600 
1CX3 78 70 90 1.472 1.667 0.833 491400 
1BNA 66 74 126 14.861 21.778 8.028 615384 
 
 
